China Biologic Products 10-K 25 Feb 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Feb. 25, 2016	Jun. 30, 2015
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Registrant Name	China Biologic Products, Inc.
Entity Central Index Key	1,369,868
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Public Float			$ 1,983
Trading Symbol	CBPO
Entity Common Stock, Shares Outstanding		26,590,974

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets
Cash and cash equivalents	$ 144,937,893	$ 80,820,224
Restricted cash deposits	0	63,677,610
Time deposits	38,032,593	0
Accounts receivable, net of allowance for doubtful accounts	25,144,969	19,402,820
Inventories	126,395,312	101,304,932
Prepayments and other current assets, net of allowance for doubtful accounts	24,545,597	14,781,658
Deposits related to land use rights, current portion	10,056,200	0
Total Current Assets	369,112,564	279,987,244
Property, plant and equipment, net	105,364,251	80,230,888
Land use rights, net	23,576,300	11,909,136
Deposits related to land use rights	0	12,792,355
Restricted cash and cash deposits, excluding current portion	0	40,230,250
Equity method investment	8,718,133	18,221,777
Loan receivable	39,834,173	0
Other non-current assets	4,861,075	3,475,442
Total Assets	551,466,496	446,847,092
Current Liabilities
Short-term bank loans, including current portion of long-term bank loans	0	57,902,600
Accounts payable	9,681,835	4,829,350
Other payables and accrued expenses	57,462,563	49,692,757
Income tax payable	4,510,986	8,257,133
Total Current Liabilities	71,655,384	120,681,840
Long-term bank loans, excluding current portion	0	40,000,000
Deferred income	4,525,867	2,765,024
Other liabilities	8,323,446	8,138,498
Total Liabilities	84,504,697	171,585,362
Stockholders' Equity
Common stock: par value $0.0001; 100,000,000 shares authorized; 28,835,053 and 27,865,871 shares issued at December 31, 2015 and 2014, respectively; 26,580,349 and 24,806,167 shares outstanding at December 31, 2015 and 2014, respectively	2,884	2,787
Additional paid-in capital	105,079,845	24,008,281
Treasury stock: 2,254,704 and 3,059,704 shares at December 31, 2015 and 2014, respectively, at cost	(56,425,094)	(76,570,621)
Retained earnings	333,704,094	244,661,391
Accumulated other comprehensive income	(18,605)	19,985,189
Total equity attributable to China Biologic Products, Inc.	382,343,124	212,087,027
Noncontrolling interest	84,618,675	63,174,703
Total Stockholders' Equity	$ 466,961,799	$ 275,261,730
Commitments and contingencies
Total Liabilities and Stockholders' Equity	$ 551,466,496	$ 446,847,092

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Common Stock, Par Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	28,835,053	27,865,871
Common Stock, Shares, Outstanding	26,580,349	24,806,167
Treasury Stock, Shares	2,254,704	3,059,704

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Sales	$ 296,457,902	$ 243,251,658	$ 203,356,856
Cost of sales	106,482,626	80,025,375	65,484,153
Gross profit	189,975,276	163,226,283	137,872,703
Operating expenses
Selling expenses	9,973,449	10,707,409	10,643,149
General and administrative expenses	41,391,520	32,129,985	36,073,871
Research and development expenses	6,024,368	4,161,901	4,223,165
Provision for other receivables in respect of an employee housing development project	0	5,068,075	0
Income from operations	132,585,939	111,158,913	86,932,518
Other income (expenses)
Equity in (loss) income of an equity method investee	(1,311,278)	8,646,181	2,170,473
Interest income	5,551,105	6,644,886	4,433,326
Interest expense	(1,727,335)	(3,697,819)	(1,134,952)
Total other income, net	2,512,492	11,593,248	5,468,847
Earnings before income tax expense	135,098,431	122,752,161	92,401,365
Income tax expense	20,992,913	26,639,527	15,540,301
Net income	114,105,518	96,112,634	76,861,064
Less: Net income attributable to noncontrolling interest	25,062,815	25,195,794	22,259,513
Net income attributable to China Biologic Products, Inc.	$ 89,042,703	$ 70,916,840	$ 54,601,551
Net income per share of common stock:
Basic	$ 3.40	$ 2.85	$ 2.05
Diluted	$ 3.27	$ 2.71	$ 1.96
Weighted average shares used in computation:
Basic	25,599,153	24,427,196	26,410,819
Diluted	26,567,366	25,685,064	27,572,111
Net income	$ 114,105,518	$ 96,112,634	$ 76,861,064
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	(24,368,360)	(1,918,715)	9,126,218
Comprehensive income	89,737,158	94,193,919	85,987,282
Less: Comprehensive income attributable to noncontrolling interest	20,698,249	24,798,384	23,951,559
Comprehensive income attributable to China Biologic Products, Inc.	$ 69,038,909	$ 69,395,535	$ 62,035,723

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated other comprehensive income [Member]	Equity Attributable To China Biologic Products, Inc. [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2012	$ 257,419,164	$ 2,663	$ 62,251,731	$ 0	$ 119,143,000	$ 14,072,322	$ 195,469,716	$ 61,949,448
Balance (in shares) at Dec. 31, 2012		26,629,615
Net income	76,861,064	$ 0	0	0	54,601,551	0	54,601,551	22,259,513
Other comprehensive income	9,126,218	0	0	0	0	7,434,172	7,434,172	1,692,046
Dividend declared to noncontrolling interest shareholders	(18,323,710)	0	0	0	0	0	0	(18,323,710)
Acquisition of noncontrolling interests	(1,963,913)	0	(664,662)	0	0	0	(664,662)	(1,299,251)
Share repurchase	(29,594,080)	0	0	(29,594,080)	0	0	(29,594,080)	0
Share-based compensation	5,050,796	0	5,050,796	0	0	0	5,050,796	0
Common stock issued in connection with:
Exercise of stock options	5,394,070	$ 65	5,394,005	0	0	0	5,394,070	0
Exercise of stock options (in shares)		648,379
Vesting of restricted shares	0	$ 6	(6)	0	0	0	0	0
Vesting of restricted shares (in shares)		63,750
Balance at Dec. 31, 2013	303,969,609	$ 2,734	72,031,864	(29,594,080)	173,744,551	21,506,494	237,691,563	66,278,046
Balance (in shares) at Dec. 31, 2013		27,341,744
Net income	96,112,634	$ 0	0	0	70,916,840	0	70,916,840	25,195,794
Other comprehensive income	(1,918,715)	0	0	0	0	(1,521,305)	(1,521,305)	(397,410)
Dividend declared to noncontrolling interest shareholders	(13,056,733)	0	0	0	0	0	0	(13,056,733)
Acquisition of noncontrolling interests	(83,925,654)	0	(68,802,855)	0	0	0	(68,802,855)	(15,122,799)
Share repurchase	(70,000,000)	0	0	(70,000,000)	0	0	(70,000,000)	0
Share-based compensation	5,396,271	0	5,396,271	0	0	0	5,396,271	0
Excess tax benefits from stock option exercises	1,611,399	0	1,333,594	0	0	0	1,333,594	277,805
Reissuance of treasury stock	33,212,518	0	10,189,059	23,023,459	0	0	33,212,518	0
Common stock issued in connection with:
Exercise of stock options	3,860,401	$ 42	3,860,359	0	0	0	3,860,401	0
Exercise of stock options (in shares)		417,002
Vesting of restricted shares	0	$ 11	(11)	0	0	0	0	0
Vesting of restricted shares (in shares)		107,125
Balance at Dec. 31, 2014	275,261,730	$ 2,787	24,008,281	(76,570,621)	244,661,391	19,985,189	212,087,027	63,174,703
Balance (in shares) at Dec. 31, 2014		27,865,871
Net income	114,105,518	$ 0	0	0	89,042,703	0	89,042,703	25,062,815
Other comprehensive income	(24,368,360)	0	0	0	0	(20,003,794)	(20,003,794)	(4,364,566)
Share-based compensation	12,114,272	0	12,114,272	0	0	0	12,114,272	0
Excess tax benefits from stock option exercises	1,518,702		1,225,941	0	0	0	1,225,941	292,761
Reissuance of treasury stock	80,583,959		60,438,432	20,145,527	0	0	80,583,959	0
Adjustments in noncontrolling interest resulting from capital injections	0		(452,962)	0	0	0	(452,962)	452,962
Common stock issued in connection with:
Exercise of stock options	7,745,978	$ 78	7,745,900	0	0	0	7,745,978	0
Exercise of stock options (in shares)		780,557
Vesting of restricted shares	0	$ 19	(19)	0	0	0	0	0
Vesting of restricted shares (in shares)		188,625
Balance at Dec. 31, 2015	$ 466,961,799	$ 2,884	$ 105,079,845	$ (56,425,094)	$ 333,704,094	$ (18,605)	$ 382,343,124	$ 84,618,675
Balance (in shares) at Dec. 31, 2015		28,835,053

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 114,105,518	$ 96,112,634	$ 76,861,064
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	8,179,376	6,989,222	6,096,650
Amortization	854,364	758,232	1,365,734
Loss (gain) on sale of property, plant and equipment	3,024,830	172,032	(123,777)
Allowance (reversal) for doubtful accounts - accounts receivable, net	34,902	(24,462)	31,567
Allowance for doubtful accounts - other receivables and prepayments	788	5,068,075	65,094
Write-down of obsolete inventories	76,587	324,584	0
Deferred tax (benefit) expense	(170,345)	3,483,890	112,632
Share-based compensation	12,114,272	5,396,271	5,050,796
Equity in loss (income) of an equity method investee	1,311,278	(8,646,181)	(2,170,473)
Excess tax benefits from share-based compensation arrangements	(1,518,702)	(1,611,399)	0
Change in operating assets and liabilities:
Accounts receivable	(7,146,311)	(2,191,118)	(5,667,386)
Prepayment and other current assets	879,165	(9,236,125)	(624,159)
Inventories	(32,095,328)	(13,418,971)	(10,432,492)
Accounts payable	5,348,896	405,071	1,621,917
Other payables and accrued expenses	6,734,988	4,472,691	2,562,739
Deferred income	(416,185)	(224,040)	0
Income tax payable	(1,926,093)	5,683,912	(446,911)
Net cash provided by operating activities	109,392,000	93,514,318	74,302,995
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for property, plant and equipment	(38,790,998)	(17,194,201)	(20,492,159)
Payment for intangible assets and land use rights	(13,500,526)	(4,677,358)	(1,327,148)
Refund of deposits related to land use right	0	1,635,200	2,100,150
Dividends received	0	0	565,425
Purchase of time deposit	0	0	(6,608,612)
Proceeds upon maturity of time deposit	0	6,608,612	0
Proceeds from sale of property, plant and equipment and land use rights	827,020	220,135	194,749
Long-term loan lent to a third party	(40,744,167)	0	0
Receipt of government grants related to property and equipment	2,452,864	0	0
Net cash used in investing activities	(89,755,807)	(13,407,612)	(25,567,595)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised	7,745,978	3,860,401	5,394,070
Payment for share repurchase	0	(70,000,000)	(29,594,080)
Proceeds from short-term bank loans	15,770,881	44,500,340	9,693,000
Repayment of short-term bank loans	(47,201,255)	(22,833,400)	(8,014,000)
Proceeds from long-term bank loans	0	70,000,000	30,000,000
Repayment of long-term bank loans	(66,300,000)	(33,700,000)	0
Payment for cash deposit as security for bank loans	0	(104,172,005)	(30,000,000)
Maturity of deposit as security for bank loans	63,152,258	30,370,670	0
Net proceeds from reissuance of treasury stock	80,583,959	33,212,518	0
Acquisition of noncontrolling interest	0	(86,830,499)	(1,963,913)
Excess tax benefits from share-based compensation arrangements	1,518,702	1,611,399	0
Dividend paid by subsidiaries to noncontrolling interest shareholders	0	(8,846,984)	(16,931,149)
Contribution from noncontrolling interest shareholders	0	0	2,891,422
Dividend to the trial court to be held in escrow as to dispute with Jie’an	(3,690,814)	0	0
Net cash provided by (used in) financing activities	51,579,709	(142,827,560)	(38,524,650)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(7,098,233)	(597,409)	4,318,420
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	64,117,669	(63,318,263)	14,529,170
Cash and cash equivalents at beginning of year	80,820,224	144,138,487	129,609,317
Cash and cash equivalents at end of year	144,937,893	80,820,224	144,138,487
Supplemental cash flow information
Cash paid for income taxes	23,348,371	17,652,514	15,947,939
Cash paid for interest expense	1,526,807	3,150,381	347,602
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables	6,363,392	3,300,284	4,252,428
Restricted cash spent for property, plant and equipment	$ 0	$ 0	$ 2,928,421

DESCRIPTION OF BUSINESS AND SIG

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	12 Months Ended
	Dec. 31, 2015
Basis Of Presentation Significant Concentration and Risks [Abstract]
DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS	NOTE 1 – DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS China Biologic Products, Inc. (“CBP”) and its subsidiaries (collectively, the “Company”), through its subsidiaries in the People’s Republic of China (the “PRC”), is a biopharmaceutical company that is principally engaged in the research, development, manufacturing and sales of plasma-based pharmaceutical products in the PRC. The PRC subsidiaries own and operate plasma stations that purchase and collect plasma from individual donors. The plasma is processed into finished goods after passing through a series of fractionating processes. All of the Company’s plasma products are prescription medicines that require government approval before the products are sold to customers. The Company primarily sells its products to hospitals and inoculation centers directly or through distributors in the PRC. Cash Concentration The Company maintains cash balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong or may exceed the insured limits for its bank accounts in China established by China Deposit Insurance Fund Management Institution. Total cash at banks and deposits as of December 31, 2015 and December 31, 2014 amounted to $ 182,291,723 184,186,306 3,020,569 86,744 Sales Concentration The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 37.6 39.3 44.1 42.2 40.4 38.0 Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of sales during the years ended December 31, 2015, 2014 and 2013. No individual customer represented 10% or more of accounts receivables as at December 31, 2015 and 2014. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. Purchase Concentration There was one supplier, namely, Xinjiang Deyuan Bioengineering Co., Ltd. (“Xinjiang Deyuan”), that comprised 10% or more of the total purchases during the year ended December 31, 2015. No supplier that comprised 10% or more of the total purchases during the years ended December 31, 2014 and 2013, respectively. There was one supplier that represented more than 10% of accounts payables as at December 31, 2015 and December 31, 2014, respectively.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation. The Company has no involvement with variable interest entities. The Company accounts for investments over which it has significant influence but not a controlling financial interest using the equity method of accounting. The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowances for doubtful accounts, the fair value determinations of stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, equity method investment and loan receivable, and accruals for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions. The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income. Revenue represents the invoiced value of products sold, net of value added taxes (VAT). Revenue is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred and the customer takes ownership and assumes risk of loss, the sales price is fixed or determinable and collection of the relevant receivable is probable. The Company mainly sells human albumin and human immunoglobulin to hospitals, inoculation centers and pharmaceutical distributors. For all sales, the Company requires a signed contract or purchase order, which specify pricing, quantity and product specifications. Delivery of the product occurs when the customer receives the product, which is when the risks and rewards of ownership have been transferred. Delivery is evidenced by signed customer acknowledgement. The Company’s sales agreements do not provide the customer the right of return, unless the product is defective in which case the Company allows for an exchange of product or return. For the periods presented, defective product returns were inconsequential. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. See Note 18 to the Consolidated Financial Statements. Cash and cash equivalents include cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. Cash and cash equivalents at December 31, 2015 and 2014 include $ 85,422,000 38,489,045 December 31, 2015 December 31, 2014 USD USD PRC, excluding Hong Kong 130,319,811 77,627,358 U.S. 13,939,319 2,651,088 Total 144,259,130 80,278,446 Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers. Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. Cost of work in progress and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand. Property, plant and equipment are stated at cost. Depreciation and amortization of property, plant and equipment attributable to manufacturing activities is capitalized as part of inventories, and recognized as cost of revenues when the inventory is sold. Cost incurred in the construction of property, plant and equipment, including process payments and deposits, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Buildings 30 Machinery and equipment 10 Furniture, fixtures, office equipment and vehicles 5 10 When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and the proceeds received thereon. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized and amortized over the remaining useful life. Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20 50 Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attaching to them and the grants will be received. Grants that compensate research and development expenses are recognized as a reduction to the related research and development expenses. Grants that compensate the Company for the cost of property, plant and equipment and land use rights are recognized as deferred income and are recognized over the useful life of the asset by way of other income. For the year ended December 31, 2015, the Company received government grants of RMB 15,000,000 2,452,864 118,751 7,280,600 1,188,907 For the year ended December 31, 2014, government grants of RMB 12,963,600 2,111,770 For the year ended December 31, 2012, the Company received government grants of RMB 18,350,000 2,989,215 297,434 224,191 Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 50 Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2015, 2014 and 2013 were $ 6,024,368 4,161,901 4,223,165 The Company’s products are covered by two separate product liability insurances each with coverages of approximately $ 3,220,000 20,000,000 Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period during which an employee is required to provide service in exchange for the award, which generally is the vesting period. Long-lived assets, such as property, plant and equipment, and purchased intangible asset subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Basic net income per share of common stock is computed by dividing net income attributable to common stockholders by the weighted average number of common stock outstanding during the year using the two-class method. Under the two-class method, net income is allocated between common stock and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as common stockholders. Diluted net income per share is calculated by dividing net income attributable to common stockholders as adjusted for the effect of dilutive common stock equivalent, if any, by the weighted average number of common stock and dilutive common stock equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive. The Company has one operating segment, which is the manufacture and sales of human plasma products. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented. In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. The original effective date for ASU 2014-09 would have required the Company to adopt beginning in its first quarter of 2017. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for one year and permits early adoption as early as the original effective date of ASU 2014-09. Accordingly, the Company may adopt the standard in either its first quarter of 2017 or 2018. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the timing of its adoption and the impact of adopting the new revenue standard on its consolidated financial statements. In July, 2015, the FASB issued ASU No. 2015-11 (“ASU 2015-11”), Simplifying the Measurement of Inventory, which required that inventory be measured at the lower of cost and net realizable value. For public business entities, ASU 2015-11 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of beginning of an interim or annual reporting period. The Company expects that the adoption of ASU 2015-11 will not have a material impact on its consolidated financial statements or related disclosures. In November, 2015, the FASB issued ASU No. 2015-17 (“ASU 2015-17”), Balance Sheet Classification of Deferred Taxes, which required that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of beginning of an interim or annual reporting period. The Company expects that the adoption of ASU 2015-17 will not have a material impact on its consolidated financial statements or related disclosures.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2015
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
ACCOUNTS RECEIVABLE	NOTE 3 – ACCOUNTS RECEIVABLE December 31, 2015 December 31, 2014 USD USD Accounts receivable 25,588,593 19,836,768 Less: Allowance for doubtful accounts (443,624) (433,948) Total 25,144,969 19,402,820 For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Beginning balance 433,948 460,689 415,607 Provisions 34,902 6,211 31,567 Recoveries - (30,673) - Write-offs - - - Foreign currency translation adjustment (25,226) (2,279) 13,515 Ending balance 443,624 433,948 460,689

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 5 – INVENTORIES Inventories at December 31, 2015 and 2014 consisted of the following: December 31, 2015 December 31, 2014 USD USD Raw materials 57,418,230 52,010,104 Work-in-process 27,401,062 22,128,405 Finished goods 41,576,020 27,166,423 Total 126,395,312 101,304,932 Raw materials mainly comprised of the human blood plasma collected from the Company’s plasma stations. Work-in-process represented the intermediate products in the process of production. Finished goods mainly comprised plasma products. Provisions to write-down the carrying amount of obsolete inventory to its estimated net realizable value amounted to $ 76,587

OTHER RECEIVABLES IN RESPECT OF

OTHER RECEIVABLES IN RESPECT OF AN EMPLOYEE HOUSING DEVELOPMENT PROJECT	12 Months Ended
	Dec. 31, 2015
Other Income and Expenses [Abstract]
OTHER RECEIVABLES IN RESPECT OF AN EMPLOYEE HOUSING DEVELOPMENT PROJECT	NOTE 6 – OTHER RECEIVABLES IN RESPECT OF AN EMPLOYEE HOUSING DEVELOPMENT PROJECT In 2009, 107 employees, or the Employee-participants, of Shandong Taibang entered into agreements, or the Housing Project Agreements, with a real estate developer regarding a housing development project, pursuant to which the developer agreed to develop and deliver residential units to the Employee-participants by the end of 2011 and the Employee-participants paid the developer deposits equal to 80% of the purchase prices of the residential units. To assist with their deposit payment, Shandong Taibang entered into separate agreements, or the Financial Assistance Agreements, with the Employee-participants and provided them with advances of up to 50% of the purchase prices of the residential units. These advances were to be repaid by deductions from the Employee-participants’ salaries. In addition, Shandong Taibang also entered into a purchase agreement with the developer to purchase additional units in the development project and made a deposit of RMB 3,823,200 622,799 27,071,684 4,409,977 5,068,075

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 7 – PROPERTY, PLANT AND EQUIPMENT December 31, 2015 December 31, 2014 USD USD Buildings 31,505,133 32,375,433 Machinery and equipment 54,640,502 58,946,498 Furniture, fixtures, office equipment and vehicles 7,859,951 8,230,842 Total property, plant and equipment, gross 94,005,586 99,552,773 Accumulated depreciation (31,521,859) (30,779,714) Total property, plant and equipment, net 62,483,727 68,773,059 Construction in progress 26,115,927 10,237,610 Prepayment for property, plant and equipment 16,764,597 1,220,219 Property, plant and equipment, net 105,364,251 80,230,888 Depreciation expense for the years ended December 31, 2015, 2014 and 2013 was $ 8,179,376 6,989,222 6,096,650

DEPOSITS RELATED TO LAND USE RI

DEPOSITS RELATED TO LAND USE RIGHTS	12 Months Ended
	Dec. 31, 2015
Deposits Related To Land Use Rights [Abstract]
DEPOSITS RELATED TO LAND USE RIGHTS	NOTE 8 – DEPOSITS RELATED TO LAND USE RIGHTS 83,400,000 12,843,600 13,000,000 2,002,000 10,000,000 1,540,000

RESTRICTED CASH DEPOSITS

RESTRICTED CASH DEPOSITS	12 Months Ended
	Dec. 31, 2015
Restricted Cash and Investments [Abstract]
RESTRICTED CASH AND DEPOSITS	NOTE 9 – RESTRICTED CASH DEPOSITS In February 2014, the Company made time deposits of RMB 246,500,000 37,961,000 194,600,000 29,968,400 40,000,000 30,000,000 194,600,000 29,968,400 In August 2014, the Company made a time deposit of RMB 196,300,000 30,230,200 194,000,000 29,876,000

EQUITY METHOD INVESTMENT

EQUITY METHOD INVESTMENT	12 Months Ended
	Dec. 31, 2015
Equity Method Investments and Joint Ventures [Abstract]
EQUITY METHOD INVESTMENT	NOTE 10 – EQUITY METHOD INVESTMENT The Company’s equity method investment as of December 31, 2015 and 2014 represented 35 In October 2008, Shandong Taibang entered into an equity purchase agreement with one of the equity owners of Huitian (“Seller”) to acquire 35% equity interest in Huitian. In connection with this transaction, in October 2008, Taibang Biological Limited (“Taibang Biological”) entered into an entrust agreement (the “Entrust Agreement”) with Shandong Taibang and the noncontrolling interest holder of Shandong Taibang, pursuant to which, Taibang Biological would pay the cash consideration, including interest, of $ 6,502,901 44,327,887 120,000 19,548 The excess of carrying amount over the Company’s share of net assets of equity method investees, which represented goodwill, is $ 1,260,243 1,333,075 116.7 19.0 6.7

LOAN RECEIVABLE

LOAN RECEIVABLE	12 Months Ended
	Dec. 31, 2015
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
LOAN RECEIVABLE	NOTE 11 –LOAN RECEIVABLE In August 2015, the Company entered into a cooperation agreement with Xinjiang Deyuan and the controlling shareholder of Xinjiang Deyuan. Pursuant to the agreement, Guizhou Taibang agreed to provide Xinjiang Deyuan with interest-bearing loans at an interest rate of 6 300,000,000 46,200,000 July 31, 2018 Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan 258,663,461 39,834,173 41,336,539 6,365,827 Interest income of $ 496,170

BANK LOANS

BANK LOANS	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
BANK LOANS	NOTE 12 – BANK LOANS (a) Current Maturity Annual December 31, December 31, Loans date interest rate 2015 2014 USD USD Short-term bank loan, secured February 12, 2015 5.04 % - 31,602,600 Current portion of long-term bank loans August 11, 2015 See note (b) - 26,300,000 Total - 57,902,600 In August 2014, the Company entered into a credit facility agreement with CMB BJ Branch to finance the acquisition of additional equity interest in Guizhou Taibang (see Note 24). Pursuant to the facility agreement, the Company obtained a 6 194,000,000 29,876,000 196,300,000 30,230,200 Interest expense amounted to $ 1,727,335 1,178,626 347,602 The Company did not have any revolving line of credit as of December 31, 2015 and 2014. (b) Non-current December 31, December 31, 2015 2014 USD USD Long-term bank loans - 66,300,000 Less: current portion of long-term bank loans - 26,300,000 Total non-current bank loans - 40,000,000 The Company entered into a credit facility agreement with CMB NY Branch in February, 2014 to finance the share repurchase (see Note 17). Pursuant to the facility agreement, CMB NY Branch lent to the Company a 24 40,000,000 18 30,000,000 246,500,000 37,961,000 194,600,000 29,968,400 1.2 3,700,000 18 30,000,000

OTHER PAYABLES AND ACCRUED EXPE

OTHER PAYABLES AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
OTHER PAYABLES AND ACCRUED EXPENSES	NOTE 13 – OTHER PAYABLES AND ACCRUED EXPENSES December 31, 2015 December 31, 2014 USD USD Payables to potential investors (1) 9,550,588 9,756,023 Payable to Guizhou Eakan Investing Corp. (2) 2,242,240 2,371,824 Payable to Guizhou Jie’an Company (3) 1,565,052 1,599,025 Salaries and bonuses payable 13,520,721 10,591,524 Accruals for selling commission and promotion fee 2,360,933 4,288,089 Dividends payable to noncontrolling interest 5,309,920 5,616,792 Payables for construction work 7,257,489 3,595,093 Other tax payables 3,855,405 3,878,983 Advance from customers 1,934,321 945,678 Deposits received 3,615,143 1,019,172 Others 6,250,751 6,030,554 Total 57,462,563 49,692,757 (1) The payables to potential investors comprise deposits received from potential investors of $ 6,123,040 6,476,904 3,427,548 3,279,119 In 2007, Guizhou Taibang received an aggregate amount of RMB 50,960,000 7,847,840 11,200,000 1,724,800 (2) Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $ 2,242,240 2,371,824 (3) Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $ 1,565,052 1,599,025 6,480,000 997,920 1,800,000

INCOME TAX

INCOME TAX	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 14 – INCOME TAX The Company and each of its subsidiaries file separate income tax returns. The United States of America The Company is incorporated in the State of Delaware in the U.S., and is subject to U.S. federal corporate income tax at gradual rates of up to 35 British Virgin Islands Taibang Biological is incorporated in the British Virgin Islands. Under the current laws of the British Virgin Islands (BVI), Taibang Biological is not subject to tax on income or capital gains. In addition, upon payments of dividends by Taibang Biological, no British Virgin Islands withholding tax is imposed. Hong Kong Taibang Holdings (Hong Kong) Limited (“Taibang Holdings”, formerly known as “Logic Holdings (Hong Kong) Limited”) is incorporated in Hong Kong and is subject to Hong Kong’s profits tax rate of 16.5 PRC The PRC’s statutory income tax rate is 25 On February 12, 2009, Shandong Taibang received the High and New Technology Enterprise certificate from the Shandong provincial government. This certificate entitled Shandong Taibang to pay income taxes at a 15 15 According to CaiShui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of the PRC, enjoys a preferential income tax rate of 15 For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD PRC, excluding Hong Kong 147,580,488 122,116,071 98,401,673 U.S. (11,711,102) (8,032,150) (7,855,555) BVI (1,336,183) 8,625,859 2,116,243 Hong Kong 565,228 42,381 (260,996) Total 135,098,431 122,752,161 92,401,365 For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Current income tax expense 21,163,258 23,155,637 15,427,669 Deferred tax (benefit) expense (170,345) 3,483,890 112,632 20,992,913 26,639,527 15,540,301 For the Years Ended December 31, December 31, December 31, 2015 2014 2013 (in percentage to earnings before income tax expense) PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Non-deductible expenses: Share-based compensation 1.3 % 0.5 % 0.9 % Others 0.1 % 0.5 % 0.7 % Tax rate differential - (2.2) % (1.0) % Effect of PRC preferential tax rate (10.5) % (9.7) % (12.7) % Bonus deduction on research and development expenses (1.5) % (1.4) % (1.4) % Change in valuation allowance 1.3 % (0.7) % 1.7 % PRC dividend withholding tax - 7.3 % 2.8 % Tax effect of equity method investment (0.2) % 2.4 % 0.8 % Effective income tax rate 15.5 % 21.7 % 16.8 % The PRC tax rate has been used because the majority of the Company’s consolidated pre-tax earnings arise in the PRC. December 31, 2015 December 31, 2014 USD USD Deferred tax assets arising from: -Accrued expenses 3,225,045 3,345,926 -Tax loss carryforwards 8,669,632 10,401,398 Gross deferred tax assets 11,894,677 13,747,324 Less: valuation allowance (8,160,611) (6,661,139) Net deferred tax assets 3,734,066 7,086,185 Deferred tax liabilities arising from: - Intangible assets (314,109) (439,116) - Equity method investment (509,021) (3,740,259) - Dividend withholding tax (7,351,023) (7,351,023) Deferred tax liabilities (8,174,153) (11,530,398) Classification on consolidated balance sheets: Deferred tax assets – current, net (included in prepayments and other current assets) 3,225,045 3,345,926 Deferred tax liabilities - non-current, net (included in other liabilities) (7,665,132) (7,790,139) In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible and tax loss carryforwards are utilized. Management considers the scheduled reversal of deferred tax liabilities (including the impact of available carryforwards periods), projected future taxable income, and tax planning strategies in making this assessment. The deferred tax assets of $ 8,669,632 6,560,170 2,109,462 26,240,681 4,911,567 6,754,594 5,050,711 5,079,935 4,443,874 6,204,299 162,235 3,382,154 978,837 1,296,319 384,754 6,560,170 6,051,100 1,600,441 610,039 For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Beginning balance 6,661,139 7,558,590 5,887,981 Addition (deduction) during the year 1,703,771 (885,253) 1,588,875 Foreign currency translation adjustment (204,299) (12,198) 81,734 Ending balance 8,160,611 6,661,139 7,558,590 According to the prevailing PRC income tax law and relevant regulations, dividends relating to earnings accumulated beginning on January 1, 2008 that are received by non-PRC-resident enterprises from PRC-resident enterprises are subject to withholding tax at 10 34 7,351,023 74 283 As of January 1, 2013 and for each of the years ended December 31, 2013, 2014 and 2015, the Company and its subsidiaries did not have any unrecognized tax benefits, and therefore no interest or penalties related to unrecognized tax benefits were accrued. The Company does not expect that the amount of unrecognized tax benefits will change significantly within the next 12 months. The Company and each of its PRC subsidiaries file income tax returns in the United States and the PRC, respectively. The Company is subject to U.S. federal income tax examination by tax authorities for tax years beginning in 2007. According to the PRC Tax Administration and Collection Law, the statute of limitations is three years if the underpayment of taxes is due to computational errors made by the taxpayer or the withholding agent. The statute of limitations is extended to five years under special circumstances where the underpayment of taxes is more than RMB 100,000 15,400

OPTIONS AND NONVESTED SHARES

OPTIONS AND NONVESTED SHARES	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
OPTIONS AND NONVESTED SHARES	NOTE 15 – OPTIONS AND NONVESTED SHARES Options Effective May 9, 2008, the Board of Directors adopted the China Biologic Products, Inc. 2008 Equity Incentive Plan, (“the 2008 Plan”). The 2008 Plan provides for grants of stock options, stock appreciation rights, performance units, restricted stock, restricted stock units and performance shares. A total of five million shares of the Company’s common stock may be issued pursuant to the 2008 Plan. The exercise price per share for the shares to be issued pursuant to an exercise of a stock option will be no less than the fair market value per share on the grant date, except that, in the case of an incentive stock option granted to a person who holds more than 10 110 10 For the year ended December 31, 2015 and 2014, no stock options to purchase common stock were granted to any directors or employees. For the year ended December 31, 2013, stock options to purchase an aggregate of 33,000 4.00 12.26 Weighted Weighted Average Average Remaining Number of Exercise Contractual Aggregate Options Price Term in years Intrinsic Value USD USD Outstanding as of January1, 2013 2,648,609 9.39 7.65 18,374,422 Granted 33,000 10.48 Exercised (648,379) 8.32 (10,923,644) Forfeited and expired (150,854) 6.78 Outstanding as of December 31, 2013 1,882,376 9.98 7.20 35,518,897 Granted - - Exercised (417,002) 9.26 (17,529,500) Forfeited and expired (32,920) 11.44 Outstanding as of December 31, 2014 1,432,454 10.16 6.53 81,753,119 Granted - - Exercised (780,557) 9.92 (68,089,712) Forfeited and expired - - Outstanding as of December 31, 2015 651,897 10.44 5.24 86,064,461 Vested and expected to vest as of December 31, 2015 651,897 10.44 5.24 86,064,461 Exercisable as of December 31, 2015 530,647 10.57 4.92 69,985,499 The weighted average option fair value of $ 8.37 276,250 For the Years Ended December 31, 2013 Expected volatility 104.00 % Expected dividends yield 0 % Expected term (in years) 5.38 Risk-free interest rate 0.72 % Fair value of underlying common stock (per share) $ 10.48 The volatility of the Company’s common stock was estimated by management based on the historical volatility of the Company’s common stock. The risk free interest rate was based on Treasury Constant Maturity Rates published by the U.S. Federal Reserve for periods applicable to the estimated term of the options. The expected dividend yield was based on the Company’s current and expected dividend policy. For the years ended December 31, 2015, 2014 and 2013, the Company recorded stock compensation expense of $ 1,117,994 1,669,573 3,773,073 As of December 31, 2015, approximately $ 649,203 0.67 Nonvested shares For the years ended December 31, 2015, 2014 and 2013, nonvested shares were granted to certain directors and employees (collectively, the “Participant”). Pursuant to the nonvested share grant agreements between the Company and the Participant, the Participant will have all the rights of a stockholder with respect to the nonvested shares. The nonvested shares granted to directors generally vest in one or two years. The nonvested shares granted to employees generally vest in four years. Number of Grant date weighted nonvested shares average fair value USD Outstanding as of January 1, 2013 120,000 9.85 Granted 306,500 22.94 Vested (63,750) 9.85 Forfeited - - Outstanding as of December 31, 2013 362,750 20.91 Granted 299,000 51.88 Vested (107,125) 20.66 Forfeited (2,500) 9.85 Outstanding as of December 31, 2014 552,125 37.78 Granted 313,100 120.62 Vested (188,625) 34.78 Forfeited (7,500) 28.8 Outstanding as of December 31, 2015 669,100 77.49 For the years ended December 31, 2015, 2014 and 2013, the Company recorded stock compensation expense of $ 10,996,278 3,726,698 1,277,723 As of December 31, 2015, approximately $ 45,040,836 2.64

STATUTORY RESERVES

STATUTORY RESERVES	12 Months Ended
	Dec. 31, 2015
Statutory Accounting Practices [Abstract]
STATUTORY RESERVES	NOTE 16 – STATUTORY RESERVES The Company’s PRC subsidiaries are required to allocate at least 10 50 34,160,154 32,137,551

SHARE REPURCHASE

SHARE REPURCHASE	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
SHARE REPURCHASE	NOTE 17– SHARE REPURCHASE On January 27, 2014, the Company entered into a repurchase agreement with an individual shareholder, pursuant to which the Company repurchased 2,500,000 70,000,000 On August 2, 2013, the Company entered into a repurchase agreement with an individual shareholder, pursuant to which the Company repurchased 1,479,704 29,594,080

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 18 – FAIR VALUE MEASUREMENTS Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates: • Short-term financial instruments (including cash and cash equivalents, time deposit, restricted cash deposits, accounts receivable, other receivables, short-term bank loans including current portion of long-term bank loans, accounts payable, other payables and accrued expenses) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments. • Loan receivable, restricted cash and cash deposits, excluding current portion – The carrying amounts of loan receivable, restricted cash and cash deposit approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing. • Long-term bank loan excluding current portion– fair value is based on the amount of future cash flows associated with the long-term bank loan discounted at the Company’s current borrowing rate for similar debt instruments of comparable terms. The carrying value of the long-term bank loan approximate its fair value as the long-term bank loan carry variable interest rate which approximate rate currently offered by the Company’s bankers for similar debt instruments of comparable maturities.

SALES

SALES	12 Months Ended
	Dec. 31, 2015
Sales [Abstract]
SALES	NOTE 19 – SALES The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Human Albumin 111,422,258 95,547,952 89,671,619 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 125,136,104 98,389,729 77,341,616 Other Immunoglobulin products 22,518,554 19,736,027 19,682,927 Placenta Polypeptide 27,194,800 24,029,706 12,150,539 Others 10,186,186 5,548,244 4,510,155 Total 296,457,902 243,251,658 203,356,856

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 20 – COMMITMENTS AND CONTINGENCIES Commitments As of December 31, 2015, commitments outstanding for the purchase of property, plant and equipment approximated $ 30.3 As of December 31, 2015, commitments outstanding for the purchase of plasma from 2016 to 2018 85.2 Legal proceedings Dispute with Jie’an over Certain Capital Injection into Guizhou Taibang In May 2007, a 91 20,000,000 9 50,960,000 7,847,840 21.4 1,800,000 20,000,000 50,960,000 7,847,840 6,480,000 997,920 In June 2007, Jie’an brought a lawsuit against Guizhou Taibang, alleging that it had a right to acquire the 18,200,000 18,200,000 During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 In December 2013, Jie’an brought a third lawsuit against Guizhou Taibang, requesting Guizhou Taibang to register 1.8 13,809,197 2,126,616 1.8 18,339,227 2,824,241 22,639,227 3,486,441 In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the November 2013 Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie’an’s request that Jie’an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 In March 2014, Guizhou Taibang held another shareholders meeting and the shareholders passed resolutions, or the March 2014 Resolutions, that, inter alia, re-calculated the ownership percentage in Guizhou Taibang based on the November 2013 Resolutions and the additional capital injections from existing shareholders. Guizhou Taibang subsequently updated the registration with the local AIC regarding the additional capital injections in August 2014. In September 2014, Jie’an and another minority shareholder of Guizhou Taibang filed a lawsuit against Guizhou Taibang, requesting that the court declare both the November 2013 Resolutions and the March 2014 Resolutions void and instruct Guizhou Taibang to withdraw the AIC registration. In November 2014, the trial court suspended this case pending the final outcome of the third lawsuit filed by Jie’an. In October 2015, the trial court denied their request. If the pending cases with Jie’an are ultimately ruled in Jie’an’s favor, the ownership interest in Guizhou Taibang may be diluted to 80 18,339,227 2,824,241 5,040,000 776,160 1,440,000 221,760 3,682,673 567,132 Dispute with Certain Individual Investors over Certain Capital Injection into Guizhou Taibang In part due to the invalidity of the Equity Purchase Agreement with certain alleged strategic investors in May 2007, which was never approved or ratified by Guizhou Taibang’s shareholders, such investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have never been registered with the local AIC. In January 2010, one individual among such investors brought a lawsuit against Guizhou Taibang requesting to register his 14.35 In October 2010, the trial court denied such individual investor’s right as shareholders of Guizhou Taibang and his entitlement to share the dividends, which ruling was reaffirmed after a re-trial by the same trial court in December 2012. After such ruling, Guizhou Taibang attempted to return the originally received fund of RMB 34,160,000 5,260,640 11,200,000 1,724,800 As of December 31, 2015, Guizhou Taibang had maintained, on its balance sheet, payables to the investors of RMB 34,160,000 5,260,640 17,677,791 2,722,380 341,600 52,606 1

NET INCOME PER SHARE

NET INCOME PER SHARE	12 Months Ended
	Dec. 31, 2015
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NOTE 21 - NET INCOME PER SHARE For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Net income attributable to China Biologic Products, Inc. 89,042,703 70,916,840 54,601,551 Earnings allocated to participating nonvested shares (2,070,762) (1,210,895) (456,261) Net income allocated to common stockholders used in computing basic and diluted net income per common stock 86,971,941 69,705,945 54,145,290 Weighted average shares used in computing basic net income per common stock 25,599,153 24,427,196 26,410,819 Diluted effect of stock option 968,213 1,257,868 1,161,292 Weighted average shares used in computing diluted net income per common stock 26,567,366 25,685,064 27,572,111 Net income per common stock – basic 3.40 2.85 2.05 Net income per common stock – diluted 3.27 2.71 1.96 During the year ended December 31, 2015, 2014 and 2013, no option was antidilutive or excluded from the calculation of diluted net income per common stock. Further, rights issued pursuant to the stockholder rights plan (see Note 25) were excluded from the calculation of diluted net income per common stock since they were antidilutive.

CHINA BIOLOGIC PRODUCTS, INC. (

CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY)	NOTE 22 – CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY) The following represents condensed unconsolidated financial information of the Parent Company only: December 31, 2015 December 31, 2014 USD USD Cash 13,939,319 2,651,088 Prepayments and prepaid expenses 86,404 89,580 Property, plant and equipment, net 211 368 Investment in and amounts due from subsidiaries 372,035,937 279,497,751 Total Assets 386,061,871 282,238,787 Other payables and accrued expenses 3,718,747 3,851,760 Long-term loan, including current portion - 66,300,000 Total Liabilities 3,718,747 70,151,760 Total Equity 382,343,124 212,087,027 Total Liabilities and Equity 386,061,871 282,238,787 For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Equity in income of subsidiaries 100,753,805 78,948,990 62,457,106 General and administrative expenses (10,693,991) (6,008,852) (7,460,763) Other expenses, net (1,017,111) (2,023,298) (394,792) Earnings before income tax expense 89,042,703 70,916,840 54,601,551 Income tax expense - - - Net Income 89,042,703 70,916,840 54,601,551 For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Net cash (used in) provided by operating activities (3,904,038) (444,755) 197,001 Net cash used in investing activities - - - Net cash provided by financing activities 15,192,269 2,416,821 405,920 Net increase in cash 11,288,231 1,972,066 602,921 Cash at beginning of year 2,651,088 679,022 76,101 Cash at end of year 13,939,319 2,651,088 679,022

FOLLOW-ON OFFERING OF COMMON ST

FOLLOW-ON OFFERING OF COMMON STOCK	12 Months Ended
	Dec. 31, 2015
Follow on Offering of Common Stock [Abstract]
FOLLOW-ON OFFERING OF COMMON STOCK	NOTE 23 – FOLLOW-ON OFFERING OF COMMON STOCK On June 15, 2015, the Company completed a follow-on offering of 3,450,000 105.00 805,000 105,000 2,645,000 345,000 80.6 On July 2, 2014, the Company completed a follow-on offering of 1,782,500 38.00 920,000 120,000 862,500 112,500 33.2

ACQUISITION OF ADDITIONAL EQUIT

ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG	12 Months Ended
	Dec. 31, 2015
Investments, All Other Investments [Abstract]
ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG	NOTE 24 – ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG On August 25, 2014, Guiyang Dalin Biotechnology ("Guiyang Dalin"), a wholly-owned subsidiary of the Company, entered into an agreement to acquire an additional 19.84 535 76.23

STOCKHOLDER RIGHTS PLAN

STOCKHOLDER RIGHTS PLAN	12 Months Ended
	Dec. 31, 2015
Stockholder Rights Plan [Abstract]
STOCKHOLDER RIGHTS PLAN	NOTE 25 – STOCKHOLDER RIGHTS PLAN On January 8, 2015, the Board of Directors (the “Board”) adopted a stockholder rights plan (the “Rights Agreement”). Pursuant to the Rights Agreement, the Board of Directors authorized and declared a dividend distribution of one right (a “Right”) for each outstanding share of the common stock, par value $ 0.0001 0.0001 325.00 l l l The Board adopted the Rights Agreement to protect stockholders from coercive or otherwise unfair takeover tactics. In general terms, it works by imposing a significant penalty upon any person or group that acquires 15% or more of the Common Shares without the approval of the Board after January 8, 2015. As a result, the overall effect of the Rights Agreement and the issuance of the Rights may be to render more difficult or discourage a merger, tender or exchange offer or other business combination involving the Company that is not approved by the Board. However, neither the Rights Agreement nor the Rights should interfere with any merger, tender or exchange offer or other business combination approved by the Board. The Board of Directors may redeem the rights for $ 0.001

SUMMARY OF SIGNIFICANT ACCOUN31

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”), and include the financial statements of the Company and its majority owned subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation. The Company has no involvement with variable interest entities. The Company accounts for investments over which it has significant influence but not a controlling financial interest using the equity method of accounting.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowances for doubtful accounts, the fair value determinations of stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, equity method investment and loan receivable, and accruals for income tax uncertainties and other contingencies. The current economic environment has increased the degree of uncertainty inherent in those estimates and assumptions.
Foreign Currency Translation	Foreign Currency Translation The accompanying consolidated financial statements of the Company are reported in US dollar. The financial position and results of operations of the Company’s subsidiaries in the PRC are measured using the Renminbi, which is the local and functional currency of these entities. Assets and liabilities of the subsidiaries are translated at the prevailing exchange rate in effect at each period end. Revenues and expenses are translated at the average rate of exchange during the period. Translation adjustments are included in other comprehensive income.
Revenue Recognition	Revenue Recognition Revenue represents the invoiced value of products sold, net of value added taxes (VAT). Revenue is recognized when persuasive evidence of an arrangement exists, delivery of the product has occurred and the customer takes ownership and assumes risk of loss, the sales price is fixed or determinable and collection of the relevant receivable is probable. The Company mainly sells human albumin and human immunoglobulin to hospitals, inoculation centers and pharmaceutical distributors. For all sales, the Company requires a signed contract or purchase order, which specify pricing, quantity and product specifications. Delivery of the product occurs when the customer receives the product, which is when the risks and rewards of ownership have been transferred. Delivery is evidenced by signed customer acknowledgement. The Company’s sales agreements do not provide the customer the right of return, unless the product is defective in which case the Company allows for an exchange of product or return. For the periods presented, defective product returns were inconsequential.
Fair Value Measurements	Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices for identical assets or liabilities in active markets accessible to the entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1, inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The fair value measurement level of an asset or liability within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. See Note 18 to the Consolidated Financial Statements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and demand deposits. The Company considers all highly liquid investments with original maturities of three-month or less at the time of purchase to be cash equivalents. Cash and cash equivalents at December 31, 2015 and 2014 include $ 85,422,000 38,489,045 December 31, 2015 December 31, 2014 USD USD PRC, excluding Hong Kong 130,319,811 77,627,358 U.S. 13,939,319 2,651,088 Total 144,259,130 80,278,446
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and do not bear interest. Amounts collected on trade accounts receivable are included in net cash provided by operating activities in the consolidated statements of cash flows. The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses, the customers’ financial condition, the amount of accounts receivables in dispute, the accounts receivables aging and the customers’ payment patterns. The Company reviews its allowance for doubtful accounts monthly. Past due balances are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company does not have any off-balance-sheet credit exposure related to its customers.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost is determined using the weighted average method. Cost of work in progress and finished goods comprise direct materials, direct production costs and an allocation of production overheads based on normal operating capacity. Adjustments are recorded to write down the carrying amount of any obsolete and excess inventory to its estimated net realizable value based on historical and forecasted demand.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost. Depreciation and amortization of property, plant and equipment attributable to manufacturing activities is capitalized as part of inventories, and recognized as cost of revenues when the inventory is sold. Cost incurred in the construction of property, plant and equipment, including process payments and deposits, are initially capitalized as construction-in-progress and transferred into their respective asset categories when the assets are ready for their intended use, at which time depreciation commences. Buildings 30 Machinery and equipment 10 Furniture, fixtures, office equipment and vehicles 5 10 When items are retired or otherwise disposed of, income is charged or credited for the difference between net book value and the proceeds received thereon. Ordinary maintenance and repairs are charged to expense as incurred, and replacements and betterments are capitalized and amortized over the remaining useful life.
Equity Method Investment	Equity Method Investment Investment in an investee in which the Company has the ability to exercise significant influence, but does not have a controlling interest is accounted for using the equity method. Significant influence is generally presumed to exist when the Company has an ownership interest in the voting stock between 20 50
Government Grants	Government Grants Government grants are recognized when there is reasonable assurance that the Company will comply with the conditions attaching to them and the grants will be received. Grants that compensate research and development expenses are recognized as a reduction to the related research and development expenses. Grants that compensate the Company for the cost of property, plant and equipment and land use rights are recognized as deferred income and are recognized over the useful life of the asset by way of other income. For the year ended December 31, 2015, the Company received government grants of RMB 15,000,000 2,452,864 118,751 7,280,600 1,188,907 For the year ended December 31, 2014, government grants of RMB 12,963,600 2,111,770 For the year ended December 31, 2012, the Company received government grants of RMB 18,350,000 2,989,215 297,434 224,191
Land Use Rights	Land Use Rights Land use rights represent the exclusive right to occupy and use a piece of land in the PRC for a specified contractual term. Land use rights are carried at cost, less accumulated amortization. Amortization is calculated using the straight-line method over the contractual period of the rights ranging from 40 50
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development expenses for the years ended December 31, 2015, 2014 and 2013 were $ 6,024,368 4,161,901 4,223,165
Product Liability	Product Liability The Company’s products are covered by two separate product liability insurances each with coverages of approximately $ 3,220,000 20,000,000
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of comprehensive income in the period that includes the enactment date. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.
Share-based Payment	Share-based Payment The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award and recognizes the cost over the period during which an employee is required to provide service in exchange for the award, which generally is the vesting period.
Long-lived Assets	Long-lived Assets Long-lived assets, such as property, plant and equipment, and purchased intangible asset subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.
Net Income per Share	Net Income per Share Basic net income per share of common stock is computed by dividing net income attributable to common stockholders by the weighted average number of common stock outstanding during the year using the two-class method. Under the two-class method, net income is allocated between common stock and other participating securities based on their participating rights in undistributed earnings. The Company’s nonvested shares were considered participating securities since the holders of these securities participate in dividends on the same basis as common stockholders. Diluted net income per share is calculated by dividing net income attributable to common stockholders as adjusted for the effect of dilutive common stock equivalent, if any, by the weighted average number of common stock and dilutive common stock equivalent outstanding during the year. Potential dilutive securities are not included in the calculation of diluted earnings per share if the impact is anti-dilutive.
Segment Reporting	Segment Reporting The Company has one operating segment, which is the manufacture and sales of human plasma products. Substantially all of the Company’s operations and customers are located in the PRC, and therefore, no geographic information is presented.
Contingencies	Contingencies In the normal course of business, the Company is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations and tax matters. An accrual for a loss contingency is recognized when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Legal costs incurred in connection with loss contingencies are expensed as incurred.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the existing accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to customers. The original effective date for ASU 2014-09 would have required the Company to adopt beginning in its first quarter of 2017. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606) – Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for one year and permits early adoption as early as the original effective date of ASU 2014-09. Accordingly, the Company may adopt the standard in either its first quarter of 2017 or 2018. The new revenue standard may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of adoption. The Company is currently evaluating the timing of its adoption and the impact of adopting the new revenue standard on its consolidated financial statements. In July, 2015, the FASB issued ASU No. 2015-11 (“ASU 2015-11”), Simplifying the Measurement of Inventory, which required that inventory be measured at the lower of cost and net realizable value. For public business entities, ASU 2015-11 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of beginning of an interim or annual reporting period. The Company expects that the adoption of ASU 2015-11 will not have a material impact on its consolidated financial statements or related disclosures. In November, 2015, the FASB issued ASU No. 2015-17 (“ASU 2015-17”), Balance Sheet Classification of Deferred Taxes, which required that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. For public business entities, ASU 2015-17 is effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted for all entities as of beginning of an interim or annual reporting period. The Company expects that the adoption of ASU 2015-17 will not have a material impact on its consolidated financial statements or related disclosures.

SUMMARY OF SIGNIFICANT ACCOUN32

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of cash at banks	As of December 31, 2015 and 2014, the Company maintained cash and cash equivalents at banks in the following locations: December 31, 2015 December 31, 2014 USD USD PRC, excluding Hong Kong 130,319,811 77,627,358 U.S. 13,939,319 2,651,088 Total 144,259,130 80,278,446

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2015
SCHEDULE OF ACCOUNTS RECEIVABLE	Accounts receivable at December 31, 2015 and 2014 consisted of the following: December 31, 2015 December 31, 2014 USD USD Accounts receivable 25,588,593 19,836,768 Less: Allowance for doubtful accounts (443,624) (433,948) Total 25,144,969 19,402,820
Accounts Receivable [Member]
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts – accounts receivable for the years ended December 31, 2015, 2014 and 2013 are as follows: For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Beginning balance 433,948 460,689 415,607 Provisions 34,902 6,211 31,567 Recoveries - (30,673) - Write-offs - - - Foreign currency translation adjustment (25,226) (2,279) 13,515 Ending balance 443,624 433,948 460,689

PREPAYMENTS AND OTHER CURRENT A

PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)	12 Months Ended
	Dec. 31, 2015
Other Receivables And Prepayments [Member]
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts – other receivables and prepayments for the years ended December 31, 2015, 2014 and 2013 are as follows: For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Beginning balance 5,207,840 142,951 75,704 Provisions 788 5,068,075 65,094 Recoveries - - - Write-offs - - - Foreign currency translation adjustment (284,565) (3,186) 2,153 Ending balance 4,924,063 5,207,840 142,951

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories at December 31, 2015 and 2014 consisted of the following: December 31, 2015 December 31, 2014 USD USD Raw materials 57,418,230 52,010,104 Work-in-process 27,401,062 22,128,405 Finished goods 41,576,020 27,166,423 Total 126,395,312 101,304,932

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment at December 31, 2015 and 2014 consisted of the following: December 31, 2015 December 31, 2014 USD USD Buildings 31,505,133 32,375,433 Machinery and equipment 54,640,502 58,946,498 Furniture, fixtures, office equipment and vehicles 7,859,951 8,230,842 Total property, plant and equipment, gross 94,005,586 99,552,773 Accumulated depreciation (31,521,859) (30,779,714) Total property, plant and equipment, net 62,483,727 68,773,059 Construction in progress 26,115,927 10,237,610 Prepayment for property, plant and equipment 16,764,597 1,220,219 Property, plant and equipment, net 105,364,251 80,230,888

BANK LOANS (Tables)

BANK LOANS (Tables)	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
SCHEDULE OF SHORT-TERM BANK LOANS	The Company’s bank loans at December 31, 2015 and 2014 consisted of the following: Maturity Annual December 31, December 31, Loans date interest rate 2015 2014 USD USD Short-term bank loan, secured February 12, 2015 5.04 % - 31,602,600 Current portion of long-term bank loans August 11, 2015 See note (b) - 26,300,000 Total - 57,902,600
SCHDULE OF NON-CURRENT LONG TERM BANK LOANS	December 31, December 31, 2015 2014 USD USD Long-term bank loans - 66,300,000 Less: current portion of long-term bank loans - 26,300,000 Total non-current bank loans - 40,000,000

OTHER PAYABLES AND ACCRUED EX38

OTHER PAYABLES AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES	Other payables and accrued expenses at December 31, 2015 and 2014 consisted of the following: December 31, 2015 December 31, 2014 USD USD Payables to potential investors (1) 9,550,588 9,756,023 Payable to Guizhou Eakan Investing Corp. (2) 2,242,240 2,371,824 Payable to Guizhou Jie’an Company (3) 1,565,052 1,599,025 Salaries and bonuses payable 13,520,721 10,591,524 Accruals for selling commission and promotion fee 2,360,933 4,288,089 Dividends payable to noncontrolling interest 5,309,920 5,616,792 Payables for construction work 7,257,489 3,595,093 Other tax payables 3,855,405 3,878,983 Advance from customers 1,934,321 945,678 Deposits received 3,615,143 1,019,172 Others 6,250,751 6,030,554 Total 57,462,563 49,692,757 (1) The payables to potential investors comprise deposits received from potential investors of $ 6,123,040 6,476,904 3,427,548 3,279,119 In 2007, Guizhou Taibang received an aggregate amount of RMB 50,960,000 7,847,840 11,200,000 1,724,800 (2) Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $ 2,242,240 2,371,824 (3) Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $ 1,565,052 1,599,025 6,480,000 997,920 1,800,000

INCOME TAX (Tables)

INCOME TAX (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS	The components of earnings (losses) before income tax expense by jurisdictions are as follows: For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD PRC, excluding Hong Kong 147,580,488 122,116,071 98,401,673 U.S. (11,711,102) (8,032,150) (7,855,555) BVI (1,336,183) 8,625,859 2,116,243 Hong Kong 565,228 42,381 (260,996) Total 135,098,431 122,752,161 92,401,365
SCHEDULE OF INCOME TAX EXPENSE	Income tax expense for the years ended December 31, 2015, 2014 and 2013 represents current income tax expense and deferred tax (benefit) expense: For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Current income tax expense 21,163,258 23,155,637 15,427,669 Deferred tax (benefit) expense (170,345) 3,483,890 112,632 20,992,913 26,639,527 15,540,301
SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE	The effective income tax rate based on income tax expense and earnings before income taxes reported in the consolidated statements of comprehensive income differs from the PRC statutory income tax rate of 25% due to the following: For the Years Ended December 31, December 31, December 31, 2015 2014 2013 (in percentage to earnings before income tax expense) PRC statutory income tax rate 25.0 % 25.0 % 25.0 % Non-deductible expenses: Share-based compensation 1.3 % 0.5 % 0.9 % Others 0.1 % 0.5 % 0.7 % Tax rate differential - (2.2) % (1.0) % Effect of PRC preferential tax rate (10.5) % (9.7) % (12.7) % Bonus deduction on research and development expenses (1.5) % (1.4) % (1.4) % Change in valuation allowance 1.3 % (0.7) % 1.7 % PRC dividend withholding tax - 7.3 % 2.8 % Tax effect of equity method investment (0.2) % 2.4 % 0.8 % Effective income tax rate 15.5 % 21.7 % 16.8 %
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	As of December 31, 2015 and 2014, significant temporary differences between the tax basis and financial statement basis of assets and liabilities that gave rise to deferred taxes were principally related to the following: December 31, 2015 December 31, 2014 USD USD Deferred tax assets arising from: -Accrued expenses 3,225,045 3,345,926 -Tax loss carryforwards 8,669,632 10,401,398 Gross deferred tax assets 11,894,677 13,747,324 Less: valuation allowance (8,160,611) (6,661,139) Net deferred tax assets 3,734,066 7,086,185 Deferred tax liabilities arising from: - Intangible assets (314,109) (439,116) - Equity method investment (509,021) (3,740,259) - Dividend withholding tax (7,351,023) (7,351,023) Deferred tax liabilities (8,174,153) (11,530,398) Classification on consolidated balance sheets: Deferred tax assets – current, net (included in prepayments and other current assets) 3,225,045 3,345,926 Deferred tax liabilities - non-current, net (included in other liabilities) (7,665,132) (7,790,139)
SUMMARY OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSETS	The following table presents the movement of the valuation allowance for deferred tax assets for the years ended December 31, 2015, 2014 and 2013: For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Beginning balance 6,661,139 7,558,590 5,887,981 Addition (deduction) during the year 1,703,771 (885,253) 1,588,875 Foreign currency translation adjustment (204,299) (12,198) 81,734 Ending balance 8,160,611 6,661,139 7,558,590

OPTIONS AND NONVESTED SHARES (T

OPTIONS AND NONVESTED SHARES (Tables)	12 Months Ended
	Dec. 31, 2015
Options and Nonvested Shares [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	A summary of stock options activity for the years ended December 31, 2015, 2014 and 2013 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Contractual Aggregate Options Price Term in years Intrinsic Value USD USD Outstanding as of January1, 2013 2,648,609 9.39 7.65 18,374,422 Granted 33,000 10.48 Exercised (648,379) 8.32 (10,923,644) Forfeited and expired (150,854) 6.78 Outstanding as of December 31, 2013 1,882,376 9.98 7.20 35,518,897 Granted - - Exercised (417,002) 9.26 (17,529,500) Forfeited and expired (32,920) 11.44 Outstanding as of December 31, 2014 1,432,454 10.16 6.53 81,753,119 Granted - - Exercised (780,557) 9.92 (68,089,712) Forfeited and expired - - Outstanding as of December 31, 2015 651,897 10.44 5.24 86,064,461 Vested and expected to vest as of December 31, 2015 651,897 10.44 5.24 86,064,461 Exercisable as of December 31, 2015 530,647 10.57 4.92 69,985,499
SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS	the Black-Scholes option pricing model using the following weighted average assumptions: For the Years Ended December 31, 2013 Expected volatility 104.00 % Expected dividends yield 0 % Expected term (in years) 5.38 Risk-free interest rate 0.72 % Fair value of underlying common stock (per share) $ 10.48
SCHEDULE OF NONVESTED SHARES ACTIVITY	A summary of nonvested shares activity for the year ended December 31, 2015, 2014 and 2013 is as follow: Number of Grant date weighted nonvested shares average fair value USD Outstanding as of January 1, 2013 120,000 9.85 Granted 306,500 22.94 Vested (63,750) 9.85 Forfeited - - Outstanding as of December 31, 2013 362,750 20.91 Granted 299,000 51.88 Vested (107,125) 20.66 Forfeited (2,500) 9.85 Outstanding as of December 31, 2014 552,125 37.78 Granted 313,100 120.62 Vested (188,625) 34.78 Forfeited (7,500) 28.8 Outstanding as of December 31, 2015 669,100 77.49

SALES (Tables)

SALES (Tables)	12 Months Ended
	Dec. 31, 2015
Sales Disclosure [Abstract]
SCHEDULE OF SALES BY PRODUCT TYPE	The Company’s sales by significant types of product for the years ended December 31, 2015, 2014 and 2013 are as follows: For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Human Albumin 111,422,258 95,547,952 89,671,619 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 125,136,104 98,389,729 77,341,616 Other Immunoglobulin products 22,518,554 19,736,027 19,682,927 Placenta Polypeptide 27,194,800 24,029,706 12,150,539 Others 10,186,186 5,548,244 4,510,155 Total 296,457,902 243,251,658 203,356,856

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2015
Net Income Loss Per Share Disclosure [Abstract]
SCHEDULE OF EPS - BASIC AND DILUTED	The following table sets forth the computation of basic and diluted net income per share of common stock for the periods indicated: For the Years Ended December 31, December 31, December 31, 2015 2014 2013 USD USD USD Net income attributable to China Biologic Products, Inc. 89,042,703 70,916,840 54,601,551 Earnings allocated to participating nonvested shares (2,070,762) (1,210,895) (456,261) Net income allocated to common stockholders used in computing basic and diluted net income per common stock 86,971,941 69,705,945 54,145,290 Weighted average shares used in computing basic net income per common stock 25,599,153 24,427,196 26,410,819 Diluted effect of stock option 968,213 1,257,868 1,161,292 Weighted average shares used in computing diluted net income per common stock 26,567,366 25,685,064 27,572,111 Net income per common stock – basic 3.40 2.85 2.05 Net income per common stock – diluted 3.27 2.71 1.96

CHINA BIOLOGIC PRODUCTS, INC.43

CHINA BIOLOGIC PRODUCTS, INC. (PARENT COMPANY) (Tables)	12 Months Ended
	Dec. 31, 2015
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
CONDENSED BALANCE SHEETS	Condensed Balance Sheets: December 31, 2015 December 31, 2014 USD USD Cash 13,939,319 2,651,088 Prepayments and prepaid expenses 86,404 89,580 Property, plant and equipment, net 211 368 Investment in and amounts due from subsidiaries 372,035,937 279,497,751 Total Assets 386,061,871 282,238,787 Other payables and accrued expenses 3,718,747 3,851,760 Long-term loan, including current portion - 66,300,000 Total Liabilities 3,718,747 70,151,760 Total Equity 382,343,124 212,087,027 Total Liabilities and Equity 386,061,871 282,238,787
CONDENSED STATEMENTS OF COMPREHENSIVE INCOME	Condensed Statements of Comprehensive Income: For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Equity in income of subsidiaries 100,753,805 78,948,990 62,457,106 General and administrative expenses (10,693,991) (6,008,852) (7,460,763) Other expenses, net (1,017,111) (2,023,298) (394,792) Earnings before income tax expense 89,042,703 70,916,840 54,601,551 Income tax expense - - - Net Income 89,042,703 70,916,840 54,601,551
CONDENSED STATEMENTS OF CASH FLOWS	Condensed Statements of Cash Flows: For the Years Ended December 31, 2015 December 31, 2014 December 31, 2013 USD USD USD Net cash (used in) provided by operating activities (3,904,038) (444,755) 197,001 Net cash used in investing activities - - - Net cash provided by financing activities 15,192,269 2,416,821 405,920 Net increase in cash 11,288,231 1,972,066 602,921 Cash at beginning of year 2,651,088 679,022 76,101 Cash at end of year 13,939,319 2,651,088 679,022

DESCRIPTION OF BUSINESS AND S44

DESCRIPTION OF BUSINESS AND SIGNIFICANT CONCENTRATIONS AND RISKS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013
Basis Of Presentation Significant Concentration And Risk [Line Items]
Total cash at banks and deposits including insured amount	$ 182,291,723	$ 184,186,306
Cash, Insured Amount	$ 3,020,569	$ 86,744
Customers that individually comprised 10% or more of the total sales	0	0	0
Suppliers that comprised 10% or more of the total purchases	1	0	0
Customers represented 10% or more of trade receivables	0	0
Suppliers that represented more than 10% of accounts payables	1	1
Human Albumin [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	37.60%	39.30%	44.10%
Human Immunoglobulin For Intravenous Injection [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	42.20%	40.40%	38.00%

SUMMARY OF SIGNIFICANT ACCOUN45

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Dec. 31, 2015CNY (¥)
Significant Accounting Policies [Line Items]
Product liability insurance coverage	$ 3,220,000							¥ 20,000,000
Certificates of deposit	85,422,000		$ 38,489,045
Research and development expenses	6,024,368		4,161,901		$ 4,223,165
Guizhou Taibang [Member]
Significant Accounting Policies [Line Items]
Grants received						$ 2,989,215	¥ 18,350,000
Grants amortized amount	297,434		224,191
Shandong Taibang [Member]
Significant Accounting Policies [Line Items]
Grants received	2,452,864	¥ 15,000,000
Grants amortized amount	118,751
Research and Development Expense [Member]
Significant Accounting Policies [Line Items]
Grants received	$ 1,188,907	¥ 7,280,600	$ 2,111,770	¥ 12,963,600
Minimum [Member]
Significant Accounting Policies [Line Items]
Equity method investment percentage	20.00%							20.00%
Contractual period of rights	40 years	40 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Equity method investment percentage	50.00%							50.00%
Contractual period of rights	50 years	50 years

SUMMARY OF SIGNIFICANT ACCOUN46

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Cash And Cash Equivalents) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	$ 144,259,130	$ 80,278,446
United States of America, Dollars
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	13,939,319	2,651,088
PRC Excluding Hong Kong [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents at banks	$ 130,319,811	$ 77,627,358

SUMMARY OF SIGNIFICANT ACCOUN47

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule Of Estimated Useful Lives Of The Assets) (Details)	12 Months Ended
	Dec. 31, 2015
Building [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	30 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years

ACCOUNTS RECEIVABLE (Schedule O

ACCOUNTS RECEIVABLE (Schedule Of Accounts Receivable) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 25,588,593	$ 19,836,768
Less: Allowance for doubtful accounts	(443,624)	(433,948)
Total	$ 25,144,969	$ 19,402,820

ACCOUNTS RECEIVABLE (Schedule49

ACCOUNTS RECEIVABLE (Schedule Of Activity in the Allowance for Doubtful Accounts) (Details) - Accounts Receivable [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 433,948	$ 460,689	$ 415,607
Provisions	34,902	6,211	31,567
Recoveries	0	(30,673)	0
Write-offs	0	0	0
Foreign currency translation adjustment	(25,226)	(2,279)	13,515
Ending balance	$ 443,624	$ 433,948	$ 460,689

PREPAYMENTS AND OTHER CURRENT50

PREPAYMENTS AND OTHER CURRENT ASSET (Details) - Other Receivables And Prepayments [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Beginning balance	$ 5,207,840	$ 142,951	$ 75,704
Provisions	788	5,068,075	65,094
Recoveries	0	0	0
Write-offs	0	0	0
Foreign currency translation adjustment	(284,565)	(3,186)	2,153
Ending balance	$ 4,924,063	$ 5,207,840	$ 142,951

PREPAYMENTS AND OTHER CURRENT51

PREPAYMENTS AND OTHER CURRENT ASSET (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Other Receivables	$ 17,846,006	$ 7,197,778
Prepaid Expense	$ 2,206,131	$ 3,158,311

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw materials	$ 57,418,230	$ 52,010,104
Work-in-process	27,401,062	22,128,405
Finished goods	41,576,020	27,166,423
Total	$ 126,395,312	$ 101,304,932

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Write-down of obsolete inventories	$ 76,587	$ 324,584	$ 0

OTHER RECEIVABLES IN RESPECT 54

OTHER RECEIVABLES IN RESPECT OF AN EMPLOYEE HOUSING DEVELOPMENT PROJECT (Narrative) (Details)	12 Months Ended
	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014CNY (¥)
Other Receivables [Line Items]
Advance Payments To The Employee Participants	$ 4,409,977	¥ 27,071,684
Provision Made For Receivables In Respect Of The Employee Housing Development Project	5,068,075		$ 5,068,075
Shandong Taibang [Member]
Other Receivables [Line Items]
Deposits Made By Shandong Taibang With The Developer	$ 622,799			¥ 3,823,200

PROPERTY, PLANT AND EQUIPMENT55

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Depreciation	$ 8,179,376	$ 6,989,222	$ 6,096,650

PROPERTY, PLANT AND EQUIPMENT56

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 94,005,586	$ 99,552,773
Accumulated depreciation	(31,521,859)	(30,779,714)
Total property, plant and equipment, net	62,483,727	68,773,059
Construction in progress	26,115,927	10,237,610
Prepayment for property, plant and equipment	16,764,597	1,220,219
Property, plant and equipment, net	105,364,251	80,230,888
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	31,505,133	32,375,433
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	54,640,502	58,946,498
Furniture, Fixtures, Office Equipment and Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 7,859,951	$ 8,230,842

DEPOSITS RELATED TO LAND USE 57

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Jan. 31, 2014USD ($)	Jan. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2013CNY (¥)
Refunded deposits related to land use rights			$ 1,540,000	¥ 10,000,000	$ 2,002,000	¥ 13,000,000
Use Rights [Member] | Land [Member]
Payment For Refundable Deposits	$ 12,843,600	¥ 83,400,000

RESTRICTED CASH DEPOSITS (Narra

RESTRICTED CASH DEPOSITS (Narrative) (Details)	1 Months Ended						12 Months Ended
	Aug. 31, 2015USD ($)	Aug. 31, 2015CNY (¥)	Aug. 31, 2014USD ($)	Aug. 31, 2014CNY (¥)	Feb. 28, 2014USD ($)	Feb. 28, 2014CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Aug. 31, 2014CNY (¥)
Restricted Cash Deposits [Line items]
Proceeds upon maturity of time deposit							$ 0	$ 6,608,612	$ 0
Payment made for time deposits secured for loans							$ 0	$ 104,172,005	$ 30,000,000
China Merchants Bank Beijing Branch [Member] | 24 Month Loan [Member]
Restricted Cash Deposits [Line items]
Payment made for time deposits secured for loans					$ 37,961,000	¥ 246,500,000
China Merchants Bank Beijing Branch [Member] | 18 Month Loan [Member]
Restricted Cash Deposits [Line items]
Proceeds upon maturity of time deposit	$ 29,968,400	¥ 194,600,000
Payment made for time deposits secured for loans					29,968,400	¥ 194,600,000
China Merchants Bank Beijing Branch [Member] | 6 Month Loan [Member]
Restricted Cash Deposits [Line items]
Payment made for time deposits secured for loans			$ 30,230,200	¥ 196,300,000
Deposit liabilities, collateral issued, financial instruments			$ 29,876,000							¥ 194,000,000
China Merchants Bank New York Branch [Member] | 24 Month Loan [Member]
Restricted Cash Deposits [Line items]
Deposit liabilities, collateral issued, financial instruments					40,000,000
China Merchants Bank New York Branch [Member] | 18 Month Loan [Member]
Restricted Cash Deposits [Line items]
Deposit liabilities, collateral issued, financial instruments					$ 30,000,000

EQUITY METHOD INVESTMENT (Narra

EQUITY METHOD INVESTMENT (Narrative) (Details)	1 Months Ended		12 Months Ended
	Oct. 31, 2008USD ($)	Oct. 31, 2008CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)
Schedule of Equity Method Investments [Line Items]
Payments to Acquire Equity Method Investments	$ 6,502,901	¥ 44,327,887
Other General and Administrative Expense	$ 19,548	¥ 120,000
Excess Of Carrying Amount Over Company Share Of Net Assets Of Equity Method Investees			$ 1,260,243	$ 1,333,075
Gain (Loss) on Disposition of Stock in Subsidiary				19,000,000	¥ 116,700,000
Income (Loss) From Equity Method Investments			$ (1,311,278)	$ 8,646,181		$ 2,170,473
Xian Huitian Blood Products Co., Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity Method Investment, Ownership Percentage			35.00%	35.00%
Income (Loss) From Equity Method Investments				$ 6,700,000

LOAN RECEIVABLE (Narrative) (De

LOAN RECEIVABLE (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes, Loans and Financing Receivable, Net, Noncurrent, Total	$ 39,834,173	$ 0
Interest income	5,551,105	$ 6,644,886	$ 4,433,326
Xinjiang Deyuan [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Notes, Loans and Financing Receivable, Net, Noncurrent, Total	39,834,173			¥ 258,663,461
Cooperation Agreement Loan Principal Amount	$ 46,200,000			¥ 300,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%			6.00%
Debt Instrument, Maturity Date	Jul. 31, 2018
Debt Instrument, Collateral	Deyuan Shareholders 58.02% equity interest in Xinjiang Deyuan
Notes And Loans Receivable Remaining Lent Capacity	$ 6,365,827			¥ 41,336,539
Interest income	$ 496,170

BANK LOANS (SCHEDULE OF SHORT-T

BANK LOANS (SCHEDULE OF SHORT-TERM BANK LOANS) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Short-term Debt [Line Items]
Total	$ 0	$ 57,902,600
Long-Term Bank Loans Current [Member]
Short-term Debt [Line Items]
Maturity date	Aug. 11, 2015
Current portion of long-term bank loans	$ 0	26,300,000
Secured Loan [Member]
Short-term Debt [Line Items]
Maturity date	Feb. 12, 2015
Annual interest rate	5.04%
Short-term bank loan	$ 0	$ 31,602,600

BANK LOANS (SCHEDULE OF LONG-TE

BANK LOANS (SCHEDULE OF LONG-TERM BANK LOANS) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term bank loans	$ 0	$ 66,300,000
Less: current portion of long-term bank loans	0	26,300,000
Total non-current bank loans	$ 0	$ 40,000,000

BANK LOANS (Narrative) (Details

BANK LOANS (Narrative) (Details)	1 Months Ended			12 Months Ended
	Aug. 31, 2014USD ($)	Jul. 31, 2014USD ($)	Feb. 28, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Aug. 31, 2014CNY (¥)	Feb. 28, 2014CNY (¥)
Credit facility agreement, bank loans [Line items]
Short term bank loan, interest expense				$ 1,727,335	$ 1,178,626	$ 347,602
CMB BJ Branch [Member] | 6 Month Loan [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, face amount	$ 29,876,000						¥ 194,000,000
Bank loans, term	6 months
Bank loans, collateral amount	$ 30,230,200						¥ 196,300,000
CMB NY Branch [Member] | 24 Month Loan [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, face amount			$ 40,000,000
Bank loans, term			24 months
Bank loans, collateral amount			$ 37,961,000					¥ 246,500,000
Credit facility, interest rate description			3-month LIBOR plus 1.3% per annum
Credit facility, facility fee			1.20%
CMB NY Branch [Member] | 18 Month Loan [Member]
Credit facility agreement, bank loans [Line items]
Bank loans, face amount		$ 30,000,000	$ 30,000,000
Bank loans, term		18 months	18 months
Bank loans, collateral amount			$ 29,968,400					¥ 194,600,000
Bank loans, repayment		$ 3,700,000
Credit facility, interest rate description			3-month LIBOR plus 1.3% per annum
Credit facility, facility fee			1.20%

SCHEDULE OF OTHER PAYABLES AND

SCHEDULE OF OTHER PAYABLES AND ACCRUED EXPENSES (Details) - USD ($)		Dec. 31, 2015	Dec. 31, 2014
Accounts Payable And Accrued Liabilities [Line Items]
Payables to potential investors	[1]	$ 9,550,588	$ 9,756,023
Payable to Guizhou Eakan Investing Corp	[2]	2,242,240	2,371,824
Payable to Guizhou Jie’an Company	[3]	1,565,052	1,599,025
Salaries and bonuses payable		13,520,721	10,591,524
Accruals for selling commission and promotion fee		2,360,933	4,288,089
Dividends payable to noncontrolling interest		5,309,920	5,616,792
Payables for construction work		7,257,489	3,595,093
Other tax payables		3,855,405	3,878,983
Advance from customers		1,934,321	945,678
Deposits received		3,615,143	1,019,172
Others		6,250,751	6,030,554
Total		$ 57,462,563	$ 49,692,757
[1]	The payables to potential investors comprise deposits received from potential investors of $6,123,040 and $6,476,904 as of December 31, 2015 and 2014, respectively, and related interest plus penalty on these deposits totaling $3,427,548 and $3,279,119 as of December 31, 2015 and 2014, respectively. In 2007, Guizhou Taibang received an aggregate amount of RMB50,960,000 (approximately $7,847,840) from certain potential investors in connection with their subscription to purchase shares in Guizhou Taibang. In 2010, the Company refunded RMB11,200,000 (approximately $1,724,800) to one of the potential investors. According to the final judgment of the PRC Supreme Court, both the rights of these potential investors as shareholders of Guizhou Taibang and their claims for the related dividend distribution have been denied in 2013. (See Note 20)
[2]	Guizhou Taibang has payables to Guizhou Eakan Investing Corp., amounting to approximately $2,242,240 and $2,371,824 as of December 31, 2015 and 2014, respectively. The Company borrowed this interest free advance for working capital purpose for Guizhou Taibang. The balance is due on demand.
[3]	Guizhou Taibang has payables to Jie’an, a noncontrolling interest shareholder of Guizhou Taibang, amounting to approximately $1,565,052 and $1,599,025 as of December 31, 2015 and 2014, respectively. In 2007, Guizhou Taibang received additional contributions from Jie’an of RMB6,480,000 (approximately $997,920) to subscribe for 1,800,000 shares in Guizhou Taibang. However, due to a legal dispute among shareholders over raising additional capital as discussed in the legal proceeding section (see Note 20), the contribution is subject to be returned to Jie’an.

OTHER PAYABLES AND ACCRUED EX65

OTHER PAYABLES AND ACCRUED EXPENSES (Narrative) (Details)		1 Months Ended		12 Months Ended
		Dec. 31, 2007USD ($)shares	Dec. 31, 2007CNY (¥)	Dec. 31, 2010USD ($)	Dec. 31, 2010CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2007CNY (¥)shares
Accounts Payable And Accrued Liabilities [Line Items]
Payables to potential investors	[1]					$ 9,550,588	$ 9,756,023
Guizhou Eakan Investing Corp [Member]
Accounts Payable And Accrued Liabilities [Line Items]
Other payables to Guizhou Eakan Investing Corp						2,242,240	2,371,824
Potential Investors [Member]
Accounts Payable And Accrued Liabilities [Line Items]
Company refunded deposits				$ 1,724,800	¥ 11,200,000
Payables to potential investors		$ 7,847,840				6,123,040	6,476,904	¥ 50,960,000
Interest plus penalty on these deposits						3,427,548	3,279,119
payables To Jiean [Member]
Accounts Payable And Accrued Liabilities [Line Items]
Other Payables To Jiean Noncontrolling Interest						$ 1,565,052	$ 1,599,025
Additional Contribution Received From Noncontrolling Interest Shareholders		$ 997,920	¥ 6,480,000
Subscribed For Shares | shares		1,800,000						1,800,000
[1]	The payables to potential investors comprise deposits received from potential investors of $6,123,040 and $6,476,904 as of December 31, 2015 and 2014, respectively, and related interest plus penalty on these deposits totaling $3,427,548 and $3,279,119 as of December 31, 2015 and 2014, respectively. In 2007, Guizhou Taibang received an aggregate amount of RMB50,960,000 (approximately $7,847,840) from certain potential investors in connection with their subscription to purchase shares in Guizhou Taibang. In 2010, the Company refunded RMB11,200,000 (approximately $1,724,800) to one of the potential investors. According to the final judgment of the PRC Supreme Court, both the rights of these potential investors as shareholders of Guizhou Taibang and their claims for the related dividend distribution have been denied in 2013. (See Note 20)

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details)	1 Months Ended	12 Months Ended			36 Months Ended		120 Months Ended
	Jan. 31, 2008	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2016	Dec. 31, 2010	Dec. 31, 2020	Dec. 31, 2015CNY (¥)	Dec. 31, 2012USD ($)
Deferred tax assets for tax loss carryforwards		$ 8,669,632	$ 10,401,398
Deferred Tax Assets, Valuation Allowance		8,160,611	6,661,139	$ 7,558,590					$ 5,887,981
Subject to withholding tax at 10%, unless reduced by tax treaties	10.00%
Deferred tax liabilities			7,351,023
Underpayment of taxes		$ 15,400						¥ 100,000
PRC [Member]
Income Tax Rate		25.00%
The United States of America [Member]
Income Tax Rate		35.00%
U.S. federal income tax	34.00%
CBP [Member]
Deferred tax assets for tax loss carryforwards		$ 2,109,462
Tax loss carryforwards		6,204,299
Deferred Tax Assets, Valuation Allowance		1,600,441	$ 610,039
CBP [Member] | 2030 [Member]
Tax loss carryforwards expiring		162,235
CBP [Member] | 2031 [Member]
Tax loss carryforwards expiring		3,382,154
CBP [Member] | 2032 [Member]
Tax loss carryforwards expiring		978,837
CBP [Member] | 2033 [Member]
Tax loss carryforwards expiring		1,296,319
CBP [Member] | 2034 [Member]
Tax loss carryforwards expiring		$ 384,754
Hong Kong [Member]
Income Tax Rate		16.50%	16.50%	16.50%
Shandong Taibang [Member]
Preferential tax rate						15.00%
Undistributed earnings			$ 74,000,000
Shandong Taibang [Member] | Scenario, Forecast [Member]
Preferential tax rate					15.00%
Guizhou Taibang [Member] | Scenario, Forecast [Member]
Preferential tax rate							15.00%
PRC subsidiaries [Member]
Deferred tax assets for tax loss carryforwards		$ 6,560,170
Tax loss carryforwards		26,240,681
Deferred Tax Assets, Valuation Allowance		6,560,170	$ 6,051,100
Undistributed earnings		283,000,000
PRC subsidiaries [Member] | 2016 [Member]
Tax loss carryforwards expiring		4,911,567
PRC subsidiaries [Member] | 2017 [Member]
Tax loss carryforwards expiring		6,754,594
PRC subsidiaries [Member] | 2018 [Member]
Tax loss carryforwards expiring		5,050,711
PRC subsidiaries [Member] | 2019 [Member]
Tax loss carryforwards expiring		5,079,935
PRC subsidiaries [Member] | 2020 [Member]
Tax loss carryforwards expiring		$ 4,443,874

SCHEDULE OF EARNINGS (LOSSES) B

SCHEDULE OF EARNINGS (LOSSES) BEFORE INCOME TAXES BY JURISDICTIONS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
PRC, excluding Hong Kong	$ 147,580,488	$ 122,116,071	$ 98,401,673
U.S.	(11,711,102)	(8,032,150)	(7,855,555)
BVI	(1,336,183)	8,625,859	2,116,243
Hong Kong	565,228	42,381	(260,996)
Total	$ 135,098,431	$ 122,752,161	$ 92,401,365

SCHEDULE OF INCOME TAX EXPENSE

SCHEDULE OF INCOME TAX EXPENSE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current income tax expense	$ 21,163,258	$ 23,155,637	$ 15,427,669
Deferred tax (benefit) expense	(170,345)	3,483,890	112,632
Income Tax Expense	$ 20,992,913	$ 26,639,527	$ 15,540,301

SCHEDULE OF RECONCILIATION OF I

SCHEDULE OF RECONCILIATION OF INCOME TAX EXPENSE (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
PRC statutory income tax rate	25.00%	25.00%	25.00%
Non-deductible expenses:
Share-based compensation	1.30%	0.50%	0.90%
Others	0.10%	0.50%	0.70%
Tax rate differential	0.00%	(2.20%)	(1.00%)
Effect of PRC preferential tax rate	(10.50%)	(9.70%)	(12.70%)
Bonus deduction on research and development expenses	(1.50%)	(1.40%)	(1.40%)
Change in valuation allowance	1.30%	(0.70%)	1.70%
PRC dividend withholding tax	0.00%	7.30%	2.80%
Tax effect of equity method investment	(0.20%)	2.40%	0.80%
Effective income tax rate	15.50%	21.70%	16.80%

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets arising from:
-Accrued expenses	$ 3,225,045	$ 3,345,926
-Tax loss carryforwards	8,669,632	10,401,398
Gross deferred tax assets	11,894,677	13,747,324
Less: valuation allowance	(8,160,611)	(6,661,139)
Net deferred tax assets	3,734,066	7,086,185
Deferred tax liabilities arising from:
- Intangible assets	(314,109)	(439,116)
- Equity method investment	(509,021)	(3,740,259)
- Dividend withholding tax	(7,351,023)	(7,351,023)
Deferred tax liabilities	(8,174,153)	(11,530,398)
Classification on consolidated balance sheets:
Deferred tax assets - current, net (included in prepayments and other current assets)	3,225,045	3,345,926
Deferred tax liabilities - non-current, net (included in other liabilities)	$ (7,665,132)	$ (7,790,139)

SUMMARY OF VALUATION ALLOWANCE

SUMMARY OF VALUATION ALLOWANCE FOR DEFERRED TAX ASSETS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Beginning balance	$ 6,661,139	$ 7,558,590	$ 5,887,981
Addition (deduction) during the year	1,703,771	(885,253)	1,588,875
Foreign currency translation adjustment	(204,299)	(12,198)	81,734
Ending balance	$ 8,160,611	$ 6,661,139	$ 7,558,590

OPTIONS AND NONVESTED SHARES (N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	May. 09, 2008	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Warrants and Options Disclosure [Line Items]
Stock compensation expense with respect to non-vested stock option		$ 649,203
Stock compensation expense to be recognized with respect to non-vested stock option		8 months 1 day
Stock compensation expense related to nonvested shares		$ 10,996,278	$ 3,726,698	$ 1,277,723
Stock compensation expense to be recognized with respect to non-vested shares		$ 45,040,836
Stock compensation expense with respect to non-vested shares weighted average vesting period		2 years 7 months 20 days
Weighted average grant date fair value of options granted				$ 8.37
Aggregate fair value of options granted				$ 276,250
General and Administrative Expense [Member]
Warrants and Options Disclosure [Line Items]
Stock compensation expense related to options		$ 1,117,994	$ 1,669,573	$ 3,773,073
For the year ended December 31, 2013, stock options to purchase an aggregate of 33,000 common stock were granted [Member] | Directors and employees at exercise prices ranging from $4.00 to $12.26 which vested immediately [Member]
Warrants and Options Disclosure [Line Items]
Number of Options, Granted				33,000
Exercise price range, Lower range limit				$ 4
Exercise price range, Upper range limit				$ 12.26
2008 Equity Incentive Plan [Member]
Warrants and Options Disclosure [Line Items]
Stock Incentive Option Granted Percentage	10.00%
Fair Value Market Exercise Price Percentage	110.00%
Options granted terms	10 years

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - Stock Option [Member] - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at beginning	1,432,454	1,882,376	2,648,609
Number of Options, Granted	0	0	33,000
Number of Options, Exercised	(780,557)	(417,002)	(648,379)
Number of Options, Forfeited and expired	0	(32,920)	(150,854)
Number of Options, Outstanding	651,897	1,432,454	1,882,376	2,648,609
Number of Options, Vested and expected to vest	651,897
Number of Options, Exercisable	530,647
Weighted Average Exercise Price, Outstanding at beginning	$ 10.16	$ 9.98	$ 9.39
Weighted Average Exercise Price, Granted	0	0	10.48
Weighted Average Exercise Price, Exercised	9.92	9.26	8.32
Weighted Average Exercise Price, Forfeited and expired	0	11.44	6.78
Weighted Average Exercise Price, Outstanding	10.44	$ 10.16	$ 9.98	$ 9.39
Weighted Average Exercise Price, Vested and expected to vest	10.44
Weighted Average Exercise Price, Exercisable	$ 10.57
Weighted Average Remaining Contractual Term in Years, Outstanding	5 years 2 months 26 days	6 years 6 months 11 days	7 years 2 months 12 days	7 years 7 months 24 days
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	5 years 2 months 26 days
Weighted Average Remaining Contractual Term in Years, Exercisable	4 years 11 months 1 day
Aggregate Intrinsic Value, Outstanding at beginning	$ 81,753,119	$ 35,518,897	$ 18,374,422
Aggregate Intrinsic Value, Exercised	(68,089,712)	(17,529,500)	(10,923,644)
Aggregate Intrinsic Value, Outstanding	86,064,461	$ 81,753,119	$ 35,518,897	$ 18,374,422
Aggregate Intrinsic Value Vested and expected to vest	86,064,461
Aggregate Intrinsic Value, Exercisable	$ 69,985,499

SCHEDULE OF STOCK OPTIONS VALUA

SCHEDULE OF STOCK OPTIONS VALUATION ASSUMPTION (Details)	12 Months Ended
	Dec. 31, 2013$ / shares
Expected volatility	104.00%
Expected dividends yield	0.00%
Expected term (in years)	5 years 4 months 17 days
Risk-free interest rate	0.72%
Fair value of underlying common stock (per share)	$ 10.48

SCHEDULE OF NONVESTED SHARES AC

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) - Non Vested Shares [Member] - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of nonvested shares, Outstanding at beginning	552,125	362,750	120,000
Number of nonvested shares, Granted	313,100	299,000	306,500
Number of nonvested shares, Vested	(188,625)	(107,125)	(63,750)
Number of nonvested shares, Forfeited	(7,500)	(2,500)	0
Number of nonvested shares, Outstanding at ending	669,100	552,125	362,750
Grant date weighted average fair value, Outstanding at beginning	$ 37.78	$ 20.91	$ 9.85
Grant date weighted average fair value, Granted	120.62	51.88	22.94
Grant date weighted average fair value, Vested	34.78	20.66	9.85
Grant date weighted average fair value, Forfeited	28.8	9.85	0
Grant date weighted average fair value, Outstanding at ending	$ 77.49	$ 37.78	$ 20.91

STATUTORY RESERVES (Narrative)

STATUTORY RESERVES (Narrative) (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Statutory Accounting Practices [Line Items]
Allocate at least 10% of its after tax profits	10.00%	10.00%
Until the reserve balance reaches 50% of respective registered capital	50.00%	50.00%
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	$ 34,160,154	$ 32,137,551

SHARE REPURCHASE (Narrative) (D

SHARE REPURCHASE (Narrative) (Details) - USD ($)	Aug. 08, 2013	Feb. 28, 2014
Accelerated Share Repurchases [Line Items]
Treasury Stock, Shares, Acquired	1,479,704	2,500,000
Treasury Stock Value Acquired	$ 29,594,080	$ 70,000,000

SCHEDULE OF SALES BY PRODUCT TY

SCHEDULE OF SALES BY PRODUCT TYPE (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Product Information [Line Items]
Sales	$ 296,457,902	$ 243,251,658	$ 203,356,856
Human Albumin [Member]
Product Information [Line Items]
Sales	111,422,258	95,547,952	89,671,619
Human Immunoglobulin For Intravenous Injection [Member]
Product Information [Line Items]
Sales	125,136,104	98,389,729	77,341,616
Other Immunoglobulin Products [Member]
Product Information [Line Items]
Sales	22,518,554	19,736,027	19,682,927
Placenta Polypeptide [Member]
Product Information [Line Items]
Sales	27,194,800	24,029,706	12,150,539
Others [Member]
Product Information [Line Items]
Sales	$ 10,186,186	$ 5,548,244	$ 4,510,155

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended						3 Months Ended	12 Months Ended
	Nov. 30, 2010USD ($)	Nov. 30, 2010CNY (¥)	Oct. 31, 2010USD ($)	May. 31, 2009shares	Jun. 30, 2007shares	May. 31, 2007USD ($)shares	Jun. 30, 2010shares	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Dec. 31, 2014USD ($)	Dec. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)shares	Dec. 31, 2015CNY (¥)	Jan. 31, 2010	May. 31, 2007CNY (¥)shares
Denied the rights of first refusal of Jie'an over the 18,200,000 shares				18,200,000	18,200,000
Interest Expense, Total | $								$ 1,727,335		$ 3,697,819		$ 1,134,952
Plasma [Member]
Purchase commitment, period of years								from 2016 to 2018	from 2016 to 2018
Purchase commitment amount | $								$ 85,200,000
Capital Addition Purchase Commitments [Member]
Purchase commitment amount | $								$ 30,300,000
Dispute Among Guizhou Taibang Shareholders Over Raising Additional Capital [Member]
Controlling Interest Of Guizhou Taibang S Shareholders						91.00%									91.00%
Issuance of an additional 20,000,000 shares of Guizhou Taibang						20,000,000
Remaining 9% noncontrolling interest						9.00%									9.00%
Investors agreed to invest						$ 7,847,840									¥ 50,960,000
21.4%, of Guizhou Taibang's equity interests						21.40%									21.40%
Subscribed for 1,800,000 shares						1,800,000									1,800,000
Share of the 20,000,000 shares being offered						20,000,000									20,000,000
Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC							1,800,000
Company returned proceeds | ¥		¥ 34,160,000
Number of shares failed to register												1,800,000
Originally Return Amount | $			$ 5,260,640
Jiean [Member]
Investors agreed to invest						$ 997,920									¥ 6,480,000
Investor [Member]
Investors agreed to invest						$ 7,847,840									¥ 50,960,000
Dispute with Jie'an over raising additional capital [Member]
Diluted to 80%								80.00%	80.00%
Payables to Jie an for the additional funds received | ¥													¥ 5,040,000
Payables to Jie an for over-paid subscription								$ 221,760					1,440,000
Payable to Jie an for the accrued interest								567,132					¥ 3,682,673
Payment to trial court to be held in escrow								3,486,441	¥ 22,639,227
Jie S Share Of Accumulated Dividends | ¥									18,339,227		¥ 18,339,227
Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang [Member]
Penalty								$ 52,606	¥ 341,600
Penalty Imposed By The Agreement								1.00%	1.00%
Interest Expense, Total								$ 2,722,380	¥ 17,677,791
Equity Method Investment, Ownership Percentage														14.35%
Originally received funds								5,260,640	¥ 34,160,000
Another investor accepted the returned fund	$ 1,724,800	¥ 11,200,000
Dispute with Jie'an over Certain Capital Injection into Guizhou Taibang [Member]
Payables to Jie an for the additional funds received | $								$ 776,160
Common Stock, Capital Shares Reserved for Future Issuance												20,000,000

NET INCOME PER SHARE - (Schedul

NET INCOME PER SHARE - (Schedule Of Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Net income attributable to China Biologic Products, Inc.	$ 89,042,703	$ 70,916,840	$ 54,601,551
Earnings allocated to participating nonvested shares	(2,070,762)	(1,210,895)	(456,261)
Net income allocated to common stockholders used in computing basic net income per common stock	$ 86,971,941	$ 69,705,945	$ 54,145,290
Weighted average shares used in computing basic net income per common stock	25,599,153	24,427,196	26,410,819
Diluted effect of stock option	968,213	1,257,868	1,161,292
Weighted average shares used in computing diluted net income per common stock	26,567,366	25,685,064	27,572,111
Net income per common stock - basic	$ 3.40	$ 2.85	$ 2.05
Net income per common stock - diluted	$ 3.27	$ 2.71	$ 1.96

SCHEDULE OF CONDENSED BALANCE S

SCHEDULE OF CONDENSED BALANCE SHEETS (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Financial Information Disclosure [Line Items]
Cash	$ 144,937,893	$ 80,820,224	$ 144,138,487	$ 129,609,317
Prepayments and prepaid expenses	2,206,131	3,158,311
Property, plant and equipment, net	105,364,251	80,230,888
Total Assets	551,466,496	446,847,092
Other payables and accrued expenses	57,462,563	49,692,757
Total Liabilities	84,504,697	171,585,362
Total Equity	382,343,124	212,087,027
Total Liabilities and Equity	551,466,496	446,847,092
Parent [Member]
Financial Information Disclosure [Line Items]
Cash	13,939,319	2,651,088	$ 679,022	$ 76,101
Prepayments and prepaid expenses	86,404	89,580
Property, plant and equipment, net	211	368
Investment in and amounts due from subsidiaries	372,035,937	279,497,751
Total Assets	386,061,871	282,238,787
Other payables and accrued expenses	3,718,747	3,851,760
Long-term loan, including current portion	0	66,300,000
Total Liabilities	3,718,747	70,151,760
Total Equity	382,343,124	212,087,027
Total Liabilities and Equity	$ 386,061,871	$ 282,238,787

SCHEDULE OF CONDENSED STATEMENT

SCHEDULE OF CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statements Of Comprehensive Income [Line Items]
Equity in (loss) income of subsidiaries	$ (1,311,278)	$ 8,646,181	$ 2,170,473
General and administrative expenses	(41,391,520)	(32,129,985)	(36,073,871)
Earnings before income tax expense	135,098,431	122,752,161	92,401,365
Income tax expense	(20,992,913)	(26,639,527)	(15,540,301)
Net Income	114,105,518	96,112,634	76,861,064
Parent [Member]
Statements Of Comprehensive Income [Line Items]
Equity in (loss) income of subsidiaries	100,753,805	78,948,990	62,457,106
General and administrative expenses	(10,693,991)	(6,008,852)	(7,460,763)
Other expenses, net	(1,017,111)	(2,023,298)	(394,792)
Earnings before income tax expense	89,042,703	70,916,840	54,601,551
Income tax expense	0	0	0
Net Income	$ 89,042,703	$ 70,916,840	$ 54,601,551

SCHEDULE OF STATEMENTS OF CASH

SCHEDULE OF STATEMENTS OF CASH FLOWS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flow Statements, Captions [Line Items]
Net cash provided by operating activities	$ 109,392,000	$ 93,514,318	$ 74,302,995
Net cash used in investing activities	(89,755,807)	(13,407,612)	(25,567,595)
Net cash provided by (used in) financing activities	51,579,709	(142,827,560)	(38,524,650)
Net increase (decrease) in cash	64,117,669	(63,318,263)	14,529,170
Cash and cash equivalents at beginning of year	80,820,224	144,138,487	129,609,317
Cash and cash equivalents at end of year	144,937,893	80,820,224	144,138,487
Parent [Member]
Cash Flow Statements, Captions [Line Items]
Net cash provided by operating activities	(3,904,038)	(444,755)	197,001
Net cash used in investing activities	0	0	0
Net cash provided by (used in) financing activities	15,192,269	2,416,821	405,920
Net increase (decrease) in cash	11,288,231	1,972,066	602,921
Cash and cash equivalents at beginning of year	2,651,088	679,022	76,101
Cash and cash equivalents at end of year	$ 13,939,319	$ 2,651,088	$ 679,022

FOLLOW-ON OFFERING OF COMMON 84

FOLLOW-ON OFFERING OF COMMON STOCK (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	Jun. 15, 2015	Jul. 02, 2014	Jun. 30, 2015	Jul. 31, 2014
Follow On Offering Of Common Stock [Line Items]
Shares Of Common Stock That Is Offered To Sell	3,450,000	1,782,500
Shares price of additionally issued shares	$ 105	$ 38
Stock Issued During Period, Shares, Treasury Stock Reissued			805,000	920,000
Number Of Shares Sold By Stockholders			2,645,000	862,500
Purchase Option Of Additional Number Of Shares Of Common Stock From Company			105,000	120,000
Purchase Option Of Additional Number Of Shares Of Common Stock From Selling Stockholder			345,000	112,500
Proceeds from Issuance or Sale of Equity			$ 80.6	$ 33.2

ACQUISITION OF ADDITIONAL EQU85

ACQUISITION OF ADDITIONAL EQUITY INTEREST IN GUIZHOU TAIBANG (Narrative) (Details) - Aug. 25, 2014 - Guizhou Eakan Pharmaceutical Co., Ltd [Member] ¥ in Millions, $ in Millions	USD ($)	CNY (¥)
Business Acquisition [Line Items]
Acquisition of Equity Method Investment Ownership Additional Percentage	19.84%	19.84%
Business Combination, Consideration Transferred	$ 82.4	¥ 535
Equity Method Investment, Ownership Percentage	76.23%	76.23%

STOCKHOLDER RIGHTS PLAN (Narrat

STOCKHOLDER RIGHTS PLAN (Narrative) (Details) - $ / shares	Jan. 08, 2015	Dec. 31, 2015	Dec. 31, 2014
Stockholder Rights Plan [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock Exercise Price	$ 325
Description For Acquire Common Shares One	if a person or group acquires 15% or more of the Companys Common Shares (including through derivatives), then the Rights will become exercisable and each Right will entitle its holder (except the acquiring person or group) to purchase, at the Exercise Price, a number of the Companys Common Shares having a then-current market value of twice the Exercise Price;
Description For Acquire Common Shares Two	if after a person or group acquires 15% or more of the Companys Common Shares, the Company merges into another company, an acquiring entity merges into the Company or the Company sells or transfers more than 50% of its assets, cash flow or earning power, then each Right will entitle its holder (except the acquiring person or group) to purchase, for the Exercise Price, a number of shares of common stock of the person engaging in the transaction having a then-current market value of twice the Exercise Price; or
Description For Acquire Common Shares Three	after a person or group acquires 15% or more of the Companys Common Shares, the Board may, at its option, exchange the Rights (except for Rights held by the acquiring person or group), in whole or in part, for Common Shares at an exchange ratio of one Common Share per Right (subject to adjustment).
Redemption Price Per Share	$ 0.001
Series A Preferred Stock [Member]
Stockholder Rights Plan [Line Items]
Preferred Stock, Par or Stated Value Per Share	$ 0.0001